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Smoking and chronic pain are significant public health concerns. Patients with chronic
pain smoke at higher rates than the general population (Zvolensky, McMillan, Gonzalez,
& Asmundson, 2009), and the pain-smoking relationship appears to be influenced by
factors such as pain-related anxiety (Ditre, Zale, Zvolensky, & Kosiba, 2013) and
depression (Goesling, Brummett, & Hassett, 2012). To address a gap in the knowledge
base, the current study examined the effectiveness and feasibility of a 5-session,
telephone-delivered ACT intervention for smoking cessation among 45 participants
recruited from two multidisciplinary pain treatment centers. The ACT intervention was
compared to an enhanced treatment-as-usual (TAU) control condition. Rates of
depression and PTSD were high in our sample: 40% for depression, and 18% for PTSD.
Participants in the ACT condition had higher verified smoking 7-day point prevalence
abstinence at the end of treatment, with 33% of those who completed the entire ACT
treatment reporting abstinence at this time point. However, at the 3-month follow-up
assessment, only two participants in the ACT condition and one participant in the TAU
condition had quit smoking. There were no significant differences in smoking intensity
by condition, but we did observe a reduction in smoking in both conditions at the end of
treatment, and at the 3-month follow-up assessments. Regarding psychological
symptoms, all study participants demonstrated increases in depression and psychological
inflexibility. There were no differences over time or between groups regarding pain
intensity, pain interference, or pain-related anxiety. Contrary to our expectations, changes
in psychological flexibility or changes in pain-related anxiety were not predictive of
smoking outcomes at 3 months. Our findings suggest that chronic pain patients have
higher smoking cessation needs compared to the general population, as evidenced by the
high rates of depression and PTSD in our sample and the overall low rates of quitting.
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SMOKING CESSATION FOR CHRONIC PAIN PATIENTS

CHAPTER 1: INTRODUCTION
Smoking among Chronic Pain Patients
Both smoking and chronic pain are prevalent health problems in the United States.
Research suggests that approximately 22-30% of the adult US population suffers from chronic
pain (Johannes, Le, Zhou, Johnston, & Dworkin, 2010; Portenoy, Ugarte, Fuller, & Haas, 2004),
with some population based estimates showing these rates to be as high as 64% (Hardt, Jacobsen,
Goldberg, Nickel, & Buchwald, 2008). Chronic pain is defined as pain lasting beyond the 3-6
month time frame that is typically required to repair tissue damage (Task Force on Taxonomy of
the IASP, 1994). Regarding smoking, prevalence estimates in the US are around 20% in spite of
the evidence of its detrimental health effects (Centers for Disease Control, 2009). Smoking is of
particular concern among individuals with chronic pain because these persons smoke at higher
rates than the general population as evidenced by the 42% smoking prevalence found among
individuals with chronic pain from a nationally representative sample (Zvolensky et al., 2009).
Moreover, the prevalence of smoking has been shown to be as high as 54% in a clinical based
chronic pain population (Jamison, Stetson, & Winston, 1991) and as high as 68% in a hospital
based pain management center (Michna et al., 2004).
There is now clear documentation in the literature linking chronic pain and smoking, with
some evidence supporting smoking as a risk factor for chronic pain (Pisinger et al., 2011).
Indeed, in a study examining environmental tobacco exposure, Pisinger et al. (2011) found that
both smokers and nonsmokers who had been exposed to significant daily environmental tobacco
smoke (ETS), defined as five hours or more, had an increased probability of exhibiting frequent
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pain than smokers and nonsmokers who had very little exposure to ETS (OR=1.46 for nonsmokers [95%CI = 1.2-1.8], and 2.04 for smokers [95%CI = 1.4-3.0]). The authors also found
that smokers reported more frequent pain than nonsmokers in six pain locations (i.e., lower back
pain in lifting, lower back pain radiating to legs, neck and upper back pain, joint pain, abdominal
pain, and non-migraine headaches). Other studies suggest that smoking and pain have a
reciprocal relationship, forming a positive feedback loop that results in greater pain and the
maintenance of smoking behavior (Ditre, Brandon, Zale, & Meagher, 2011). This information is
highly relevant in chronic pain treatment, given that smoking among individuals with chronic
pain has been linked to worse pain outcomes (Jakobsson, 2008). Additionally, the negative
consequences of smoking, independent of the presence of chronic pain, are significant and well
documented, costing approximately $193 billion per year in medical expenses and lost
productivity (Centers for Disease Control, 2005).
Psychological Considerations
The rates of smoking among people with psychological disorders are almost twice as
high as the rates found among the general population (Lasser et al., 2000; Rohde, Lwwinsohn,
Brown, Gau, & Kahler, 2003). Although several theories have been proposed regarding the
nature of these associations, heterogeneity among people with psychological disorders has
precluded agreement regarding definitive causal models to explain the link (Ziedonis et al.,
2005). Regarding depression, some suggest smoking behavior represents an effort to lessen
depressive symptoms (Baker, Piper, McCarthy, Majeskie, & Fiore, 2004), while others propose
that smoking causes depression (Steuber & Danner, 2006). Bidirectional models have also
emerged in the literature, maintaining that smoking and depression influence each other (Windle
& Windle, 2001).
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Regarding anxiety, smoking prevalence estimates can be as high as 56% for generalized
anxiety disorder (Lasser et al., 2000). A study by Johnson et al. (2000) found heavy smoking
during adolescence and young adulthood conferred risk for developing panic disorder,
generalized anxiety disorder, and agoraphobia later in life. Unexpectedly, in this study, anxiety
disorders during adolescence did not predict smoking during young adulthood. Further,
Zvolensky, Schmidt, and McCreary (2003) found smoking to be associated with higher social
impairment, higher severity of panic symptoms, and higher intensity and severity of anxiety
symptoms among people with panic disorder. The literature provides minimal guidance
regarding mechanisms driving the relationship between anxiety and smoking, and a number of
factors are likely to play a role in this association (Ziedonis et al., 2008). Some researchers
suggest, for example, that both anxiety and smoking result from a genetic, or other
predisposition, to experience negative affect (Gilbert, 1995; R. Goodwin & Hamilton, 2002;
Ziedonis et al., 2008). Posttraumatic Stress Disorder (PTSD), a trauma-related disorder with a
substantial link to anxious affect (American Psychiatric Association, 2013), has been linked link
to smoking behavior (Beckham, 1999; Koenen et al., 2005; Lasser et al., 2000). There is
evidence that PTSD can lead to smoking, that smoking can increase the risk of developing
PTSD, and that smoking is used as a coping strategy to deal with PTSD symptoms (Koenen et
al., 2005).
Depression, anxiety, and PTSD rates are high among individuals with chronic pain
(Arnow et al., 2006; Atkinson, Slater, Patterson, Grant, & Garfin, 1991; Dersh, Polatin, &
Gatchel, 2002; Roy-Byrne, Smith, Goldberg, Afari, & Buchwald, 2004). In a study investigating
the role of depressive symptoms on smoking-related pain symptoms, Goesling et al. (2012)
found depressive symptoms to mediate the relationship between smoking and pain in terms of
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pain severity and pain interference. Current smokers in Goesling et al.’s study reported higher
depressive symptoms, higher pain severity, and higher pain interference than nonsmokers with
chronic pain. However, when the authors controlled depressive symptoms in a mediation model,
smoking status no longer demonstrated an effect on pain severity or pain interference. In another
study using a retrospective design to examine the effects of depression and smoking on pain
severity and opioid use in patients with chronic pain enrolled in a 3-week outpatient pain
treatment program, baseline pain severity was independently associated with greater levels of
depression but not with smoking status (Hooten, Shi, Gazelka, & Warner, 2011). These studies
suggest that further research is needed to understand the complex relationship between
depression, smoking status, and pain.
Ditre et al. (2013) found that pain-related anxiety accounted for a significant proportion
of the variance in smoking dependence scores, both total scores, and primary and secondary
smoking dependence scores as measured by the Wisconsin Inventory of Smoking Dependence
Motives (WISDM) (Piper et al., 2008; Piper et al., 2004). Primary dependence scores reflect the
central or core characteristics of tobacco dependence (e.g., tolerance, cravings, etc.), while
secondary dependence scores are indicative of circumstantial factors contributing to smoking
(e.g., weight control, alleviating stress, improving mood, etc.) (Piper et al., 2008). Because the
authors found pain-related anxiety to be strongly correlated with secondary dependence motives,
they deduced that smoking was motivated by a desire to cope with or escape pain-related
anxiety. Interestingly, these results held true even after controlling for generalized anxiety, pain
severity, and demographic and social factors. The authors concluded that smokers with chronic
pain may be at greater risk of persistent or increased dependence on tobacco than smokers
without chronic pain.
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In addition to depression and anxiety, evidence indicates that smoking among individuals
with chronic pain is linked to greater emotional distress, higher reliance on pain medication, and
lower levels of physical activity (Jamison et al., 1991). Further, chronic pain on its own has been
linked to psychological disorders such as depression, anxiety, substance use disorders,
personality disorders, and somatoform disorders [See Dersh et al. (2002) for full a review on
chronic pain and psychopathology]. It is no surprise that chronic pain patients have reported
smoking behavior as an attempt to help them deal with pain and relieve depressive symptoms
(Jamison et al., 1991). Interestingly, although nicotine has been found to have analgesic effects
in animal studies (Rowley, Payappilly, Lu, & Flood, 2008; Sahley & Berntson, 1979), it
increases pain intensity among chronic pain patients and is associated with increased
occupational and social impairment (Hooten et al., 2009; Weingarten et al., 2009; Weingarten et
al., 2008).
Along with mental health considerations in smoking cessation among individuals with
chronic pain, pain-related beliefs and thoughts are important to consider as potential barriers to
cessation efforts. In a study examining the extent to which individual differences in pain
perception are related to successful abstinence from smoking, Nakajima and al'Absi (2011)
found that higher pain ratings before and after a cold pressor test predicted greater risk of
smoking relapse. Higher pain ratings may therefore be useful in identifying smokers at risk of
early smoking relapse (Nakajima & al'Absi, 2011). Indeed, in a study examining smoking as a
pain coping strategy and pain patients’ awareness of the influence of smoking on their pain,
Jamison et al. (1991) found that the majority of smokers (91%) did not believe that smoking had
an effect on the intensity of their chronic back pain. However, 57% of smokers reported needing
to smoke when they were in pain, suggesting that these patients were unaware of the relationship

5

SMOKING CESSATION FOR CHRONIC PAIN PATIENTS

between their pain and their smoking. Smokers with chronic pain were also found to have more
emotional distress, to rely more heavily on medication, and to remain inactive when compared to
nonsmokers with chronic pain. The authors concluded that pain patients may be at risk for
greater smoking when they experience higher pain intensity and emotional distress.
Finally, the concept of fear-avoidance has received considerable attention in the pain
literature. Briefly, fear-avoidance refers to a tendency to fear pain signals or to interpret them as
a sign of danger and/or tissue damage (Lethem, Slade, Troup, & Bentley, 1983). In order to cope
with this fear, individuals in pain avoid certain movements and activities that may lead to pain,
which can result ultimately in physical deconditioning (Lethem et al., 1983). As individuals with
chronic pain become more physically deconditioned, they are more likely to experience pain
from simple activities and to interpret this pain as a serious sign that something is wrong, thus
maintaining a negative feedback loop (Vlayen & Linton, 2000). Pain catastrophizing, defined as
“an exaggerated negative orientation toward noxious stimuli” (Sullivan, Bishop, & Pivik, 1995)
appears to maintain this cycle (Vlayen, de Jong, Sieben, & Combez, 2002).
Pain-related fear has emerged as a contributor to the development of chronic pain. A
meta-analysis examining the relationship between pain-related fear and disability, indicated that
a positive moderate to large relationship exists between pain-related fear and disability (Zale,
Lange, Fields, & Ditre, 2013). As mentioned earlier, and of special relevance to the current
study, pain-related anxiety, a concept closely related to fear-avoidance, has also been associated
with nicotine dependence (Ditre et al., 2013). It is possible that pain-related anxiety may be an
underlying mechanism in the association between pain and smoking. This may call for targeting
pain-related anxiety in conjunction with smoking cessation treatment in order to help reduce
smoking rates and disability among persons with chronic pain.
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In sum, smoking prevalence is high among chronic pain patients (Jamison et al., 1991;
Michna et al., 2004; Zvolensky et al., 2009) who are also likely to experience high rates of
psychological disorders like depression, anxiety, and PTSD (Arnow et al., 2006; Atkinson et al.,
1991; Dersh et al., 2002; Roy-Byrne et al., 2004). The relationship between smoking and
psychological disorders is a complicated one, with biological, psychological, environmental, and
social factors playing a role in the initiation and course of smoking among individuals with
psychological disorders. However, there is evidence that addressing psychological symptoms
concurrently with smoking can result in improved smoking cessation outcomes (McFall et al.,
2010; McFall et al., 2007; Muñoz, Marín, Posner, & Pérez-Stable, 1997). As outlined above,
psychological disorders such as depression, anxiety, and PTSD appear to be linked to chronic
pain and may help explain the high rates of smoking among individuals with chronic pain.
Addressing depression, anxiety, and pain-related beliefs may be particularly beneficial in a
smoking cessation intervention for this population.
Psychological Approaches to Chronic Pain Treatment
Given that chronic pain is defined as pain lasting beyond the expected time needed for
healing (Task Force on Taxonomy of the IASP, 1994), the benefits of a singular, medical
approach to treatment are not as evident for chronic pain as they are with acute pain (Roditi &
Robinson, 2011). Indeed, for most patients with acute pain, once the apparent cause has been
addressed or once the person has had enough time to heal, the pain will end (Roditi & Robinson,
2011). However, for reasons not yet entirely understood, some patients do not achieve complete
resolution of their pain condition despite medical treatment, and they subsequently develop
chronic pain (Roditi & Robinson, 2011).

7

SMOKING CESSATION FOR CHRONIC PAIN PATIENTS

From a biopsychosocial standpoint, the experience of chronic pain includes physiological
characteristics (e.g., tissue damage), social factors (e.g., impact of chronic pain on relationships,
employment, etc.), psychological components (e.g., catastrophizing, distress associated with
chronic pain), and physical characteristics (e.g., limitations on physical function due to chronic
pain) (Roditi & Robinson, 2011). The role of psychology in chronic pain treatment is not to
“cure” or eliminate pain, but rather to help chronic pain patients increase their quality of life
while living with a chronic pain condition (Roditi & Robinson, 2011). Given the biopsychosocial
perspective, pain is best managed by a multidisciplinary, integrated approach, typically
consisting of physical therapy, analgesic medications, and psychological approaches including
cognitive and behavioral therapies (Roditi & Robinson, 2011). Psychological approaches to pain
management have shown many beneficial outcomes, such as: improved mood, greater life
satisfaction, improved pain ratings, decreased pain-related anxiety, and improved cognitive
coping and appraisal, among others (Moreley, Eccleston, & Williams, 1999; Vowles &
McCracken, 2008; Wicksell, Ahlqvist, Bring, Merlin, & Olsson, 2008).
A variety of psychological approaches have shown promise in the management of
chronic pain (Roditi & Robinson, 2011). These include cognitive and behavioral approaches,
such as cognitive-behavioral therapy (CBT), psychoeducation, coaching in coping strategies,
cognitive restructuring, and instruction in pacing, among others; biofeedback, helping the patient
recognize areas of muscular tension so that he/she can then relax those areas and reduce pain;
operant behavior therapy to extinguish unhelpful behaviors that help to maintain pain, such as
fear avoidance in response to pain-related fear (Roditi & Robinson, 2011); relaxation techniques,
such as diaphragmatic breathing, progressive muscle relaxation, and visualization/guided
imagery to help activate the parasympathetic nervous system to achieve decreases in pain; and
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acceptance-based approaches, which emphasize helping the patient live a valued life despite
his/her pain, and teaching patients to increase their psychological flexibility.
Acceptance and Commitment Therapy (ACT), one of the psychological approaches used
more recently in pain treatment, is among the therapies considered the “new wave” of CBT
(Hofmann, Sawyer, & Fang, 2010; Kahl, Winter, & Schweiger, 2012). The difference between
traditional CBT and the “new wave” or “third wave” of behavioral therapies ([e.g., Mindfulness
Based Cognitive Therapy (MBCT), Dialectical Behavior Therapy (DBT), Metacognitive
Therapy (MC))] is that the new therapies emphasize changing the function or power of
psychosocial events rather than changing the events experienced by the client (Hayes, Luoma,
Bond, Masuda, & Lillis, 2006). This is done by using mindfulness, cognitive defusion (noticing
thoughts rather than getting caught up in them), and acceptance (Hayes et al., 2006). The aim of
ACT is to help individuals construct a rich and meaningful life while accepting the
unpleasantness that inevitably comes with the human experience (Harris, 2009). According to
Harris (2009), ACT focuses on working to clarify the patient’s values and using these values to
motivate and inspire him/her to set goals and take appropriate action. In addition, the patient
incorporates mindfulness skills to help him/her cope with difficult thoughts and feelings. As the
name implies, ACT aims to teach the patient to accept circumstances that are out of her/his
control, and to commit to effective action that will result in living a life in accord to the patient’s
values.
In chronic pain treatment, ACT aims to increase functioning and minimize pain’s
interference with a patient’s ability to live a rich and fulfilling life (Hayes & Duckworth, 2006).
In a randomized controlled trial of ACT versus CBT for chronic pain in a primary care setting,
Wetherell et al. (2011) obtained improvements among both the ACT participants and the CBT
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participants on pain interference and pain-related anxiety. ACT participants who completed the
intervention reported greater satisfaction with their treatment than the CBT participants. A
similar study, comparing ACT to treatment as usual (TAU) in primary care, observed lower
depression and higher overall improvement among the ACT participants immediately post
treatment, and lower depression, lower disability and higher pain acceptance among the ACT
participants at the three-month follow-up assessment (McCracken, Sato, & Taylor, 2013).
If depression and pain-related anxiety do, in fact, play a role in the smoking behavior of
chronic pain patients, ACT strategies may be particularly useful for chronic pain patients who
smoke, given ACT’s effectiveness in reducing pain-related anxiety and depression. Indeed, as
stated earlier, pain-related anxiety was found to predict nicotine dependence among individuals
with chronic pain (Ditre et al., 2013). Addressing pain-related anxiety using ACT has the
potential to target an important factor underlying the association between chronic pain and
smoking. If. as Ditre et al. suggest, smoking is used as a coping mechanism to avoid painrelated anxiety, then addressing it specifically in a smoking cessation treatment could decrease
chronic pain patients’ risk of dependence on tobacco. Further, given that ACT has been effective
in lowering depression scores among chronic pain patients, ACT could be used to address
depression symptoms related to nicotine withdrawal in this population and to reduce the
tendency of chronic pain clients to use smoking as a coping mechanism to deal with depression
symptoms.
Smoking Cessation among Chronic Pain Patients: An Integrative Approach
The U.S. Department of Health and Human Services' (2008) Clinical Practice Guidelines
for Treating Tobacco Use and Dependence consider integration of tobacco cessation treatment to
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be an effective and efficient way of delivering treatment services to people with chronic health
conditions. Indeed, these guidelines stress the importance of targeting smokers with chronic
medical health conditions for tobacco cessation treatment interventions. While integrating
tobacco dependence treatment in chronic pain settings is crucial to reducing smoking rates in this
population, provider beliefs regarding the smoking behavior of pain patients may prevent them
from providing cessation treatment (Hooten, Vickers, et al., 2011). For example, a possible
concern in addressing smoking among chronic pain patients, especially if smoking is used as a
coping strategy to deal with pain or distress, is whether these patients are motivated to quit
smoking (Hooten, Vickers, et al., 2011). In a study investigating the role of pain in smokers'
readiness to quit, Hahn, Rayens, Kirsh, and Passik (2006) found that smokers who suffer from
significant pain were just as likely as those without significant pain to be ready to quit smoking.
Given these findings, the authors recommended placing formal tobacco dependence treatment
programs within pain clinics and addressing pain in smoking cessation programs. Additional
studies in this area have also shown that individuals with chronic pain are motivated to quit using
tobacco (Zale & Ditre, 2013; Zale, Ditre, Dorfman, Heckman, & Brandon, 2014).
Despite the high need for smoking cessation services and the fact that many chronic pain
patients appear motivated to quit, few intervention studies exist. To this author’s knowledge,
there has only been one pilot randomized controlled trial of a smoking cessation intervention
tested among chronic pain patients who smoke (Hooten et al., 2014). In one of the very few
studies in this area, Kaye, Prabhakar, Fitzmaurice, and Kaye (2012) tested a smoking cessation
intervention in pain patients that highlighted the role of physician advice to quit and investigated
its effects on patients' smoking habits. The intervention condition consisted of the pain
practitioner giving patients the following three messages at each monthly appointment:
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“1. Every cigarette has more than 50 poisonous chemicals
2. Smoking cigarettes will shorten your lifespan
3. Your current diagnosis will not improve (i.e., your pain will not lessen) if you continue
to smoke.” (p. 18).
Patients were also offered a variety of options for smoking cessation medication. Patients
rated statement 2 (smoking cigarettes will shorten your lifespan) as the most convincing,
followed by statement 3 (your current diagnosis will not improve). Statement 1 (every cigarette
has more than 50 poisonous chemicals) was the least convincing statement chosen by pain
patients. Although the study did not have a control condition, the investigators found that 91% of
patients reduced the number of cigarettes they smoked per day, with the overall number of
cigarettes smoked per day dropping from a mean of 25.5 to 7.2. In addition, patients reported
benefits from smoking reduction and cessation, including improved breathing, feeling better, and
a reduction in pain.
Hooten et al. (2009) conducted a study in a multidisciplinary pain rehabilitation
program to test an intervention for smoking cessation. The intervention consisting of a one-time,
one-hour meeting, that included the development of a brief treatment plan, use of
pharmacotherapy, and development of a relapse prevention plan as well as three follow-up
telephone calls inquiring about tobacco use and providing relapse prevention support (conducted
at one, three, and six months). None of the smokers receiving this intervention quit smoking.
This finding was consistent with the U.S. Public Health Service’s (Fiore et al., 2008) conclusion
that multiple contacts are more effective than single contacts in terms of smoking cessation
treatment. Indeed, a review of randomized controlled trials looking at the efficacy of smoking
cessation interventions delivered in hospital settings found that the most efficacious interventions
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included hospital contact and follow-up treatment contacts that continued for more than one
month after discharge (Rigotti, Munafo, Murphy, & Stead, 2003).
The latest study in this area consisted of a pilot study evaluating a seven-session (four
individual, 3 group) cognitive behavioral smoking cessation treatment for adults with chronic
pain (Hooten et al., 2014). Participants were patients at the Mayo Comprehensive Pain
Rehabilitation Center. The intervention was based on the authors’ preliminary studies indicating
that chronic pain patients use smoking as a distraction from pain and a way to cope with distress,
and they prefer group therapy over individual therapy. The control condition consisted of a onehour meeting with a trained tobacco treatment specialist who followed evidence-based practice
guidelines for treating tobacco dependence. Pharmacotherapy was available for participants in
both conditions. Results suggested that integrating smoking cessation into pain treatment may be
effective. Indeed, 20% of participants assigned to the intervention arm quit compared to 0% in
the control group. In addition, at week three, participants in the intervention condition reported
greater improvements in smoking cessation self-efficacy than participants in the control
condition. The authors concluded that integration of smoking cessation treatment in ongoing pain
treatment is feasible. The authors also asserted that the intervention did not have negative effects
on pain-related treatment outcomes.
To summarize, there are several important reasons for addressing tobacco use in
multidisciplinary pain treatment centers. First, addressing smoking in these settings is consistent
with clinical practice guidelines for treating tobacco use and dependence (U.S. Department of
Health and Human Services, 2008). Second, there is evidence that smokers with chronic pain are
motivated to quit smoking (Zale & Ditre, 2013; Zale et al., 2014), and that they are amenable to
pharmacologic intervention (Zale & Ditre, 2013). Third, smoking cessation has been found to be
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related to improved pain scores following spinal care (Behrend et al., 2012). There is also
evidence suggesting that persistent attention to smoking behavior by pain providers results in
significant reduction in smoking behavior as well as patient-reported health benefits, including
improvement in breathing, feeling better, and a reduction in pain (Kaye et al., 2012).
It is important to note that psychological approaches to the management of chronic pain
can be implemented in tobacco cessation treatment. Psychological interventions for chronic pain
include teaching patients cognitive, behavioral, and acceptance-based approaches to manage and
cope with pain conditions. The many benefits of psychological approaches in the treatment of
chronic pain include: reduced pain-related disability, reduced emotional distress, increased selfmanagement of pain, and improved pain-coping resources, among others (Roditi & Robinson,
2011). Knowledge of these pain management strategies can be beneficial in addressing smoking
cessation among patients who smoke as a coping strategy to deal with pain. Lastly, smoking
status among chronic pain patients is associated with some of the same variables as those found
in the general population, including depression and anxiety. Delivery of smoking cessation by a
trained counselor with knowledge of the relationship between mood and smoking can be helpful
for chronic pain patients who experience symptoms of depression.
ACT for Smoking Cessation
According to ACT, psychological inflexibility is at the root of most psychopathology and
human suffering (Hayes et al., 2006). In Hayes et al.’s ACT model of psychopathology, six core
processes contribute to psychological inflexibility: experiential avoidance; cognitive fusion;
attachment to the conceptualized self; inaction, impulsivity or avoidant persistence; lack of
values or clarity or contact with values; and dominance of the conceptualized past and future, or
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limited self-knowledge. In ACT, these processes are targeted with six core therapeutic
approaches: acceptance, cognitive defusion, being present, self as context, committed action, and
defining valued directions. The main goal of ACT is for patients to live their lives in contact with
the present moment and to behave in ways that are consistent with their values. In this sense, the
six core processes can be categorized into two overlapping groups: mindfulness and acceptance
processes (acceptance, defusion, contact with the present moment, and self as context), and
commitment and behavior change processes (contact with the present moment, self as context,
values, and committed action) (Hayes et al., 2006).
According to Hayes et al. (2006), the process of acceptance targets experiential
avoidance by embracing one’s experiences rather than engaging in attempts to avoid or change
these experiences. Cognitive defusion targets cognitive fusion by teaching patients to change the
function of the thoughts they experience rather than attempting to change the content of those
thoughts. Being present involves experiencing the world in a non-judgmental fashion rather than
letting oneself become dominated by fearful thoughts about the future or by a strongly held
concept of the past. Self-as-context involves being aware of the wide array of one’s experiences
without attachment to the self as “the conceptualized self.” In other words, it is the observing self
(or the space from which observing happens), rather than the thinking self. Defining valued
direction involves clarifying one’s values in several domains rather than doing things because
society or other people deem those things important. Lastly, committed action involves the
development of greater patterns of effective action related to one’s values (Hayes et al., 2006).
ACT has shown promise in smoking cessation treatment research. To date, a number of
studies have examined ACT for smoking cessation in a variety of formats: Telephone-delivered
ACT (Bricker, Bush, Zbikowski, Mercer, & Heffner, 2014; Bricker, Mann, Marek, Liu, &
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Peterson, 2010; Schimmel-Bristow, Bricker, & Comstock, 2012), group and individual ACT
sessions (Gifford et al., 2004; Hernandez-Lopez, Bricker, Roales-Nieto, & Montesinos, 2009),
web-based delivered ACT (Bricker, Wyszynski, Comstock, & Heffner, 2013), and smartphonedelivered ACT (Bricker, Mull, et al., 2014).
The first study to examine ACT for smoking cessation was conducted by Gifford et al.
(2004). The investigators tested a seven-week individual and group based ACT treatment for
smoking cessation (14 sessions total) using 124 participants who smoked and who did not have
any active psychiatric conditions. The control condition, administered by a psychiatrist and a
psychiatry resident, consisted of use of nicotine replacement therapy (NRT), patient education
and physician advice. In this condition, participants met as a group with the psychiatrist for a 1.5
hour education session providing rationale for using NRT, followed by a 30-minute session
where the participants could ask questions. Participants in this condition were instructed not to
smoke. They were also provided with basic smoking cessation advice, and with instructions on
how to reach the psychiatrist if needed.
The ACT condition was delivered by a psychologist and by three advanced psychology
students, all of whom had been trained in ACT. Participants were asked to complete seven 50minute individual sessions and seven 90-minute group sessions for a period of seven weeks (two
sessions per week). The protocol focused on teaching participants to notice their smoking
triggers, accept the ones they could not change, and take action in constructive ways when
appropriate. In addition, participants were encouraged to make public commitments to cessation
as a means of behaving in a way consistent with their values (please see Appendix 1 for a copy of
the description of the components of the intervention). In this study, the ACT condition produced
better long-term smoking cessation outcomes (35% compared to 15% in the control condition at
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the one-year follow-up assessment). There were no significant differences among conditions at
posttreatment or 6-month follow-up. Another interesting finding was that improvement in
acceptance-related skills mediated ACT outcomes, suggesting that the ACT model of smoking
cessation treatment is a valuable one.
A similar study evaluating the effectiveness of ACT for smoking cessation was
conducted in 2009 by Hernandez-Lopez et al. (2009). The authors compared a seven-week, 90minute long ACT group treatment for smoking cessation with a CBT treatment of the same
format and duration. The ACT condition employed metaphors, and experiential exercises in an
effort to help participants establish the value of quitting and to teach acceptance of thoughts and
feelings related to quitting (please see Appendix 2 for a copy of the full description of the
intervention). Essentially,the Hernandez-Lopez et al. (2009) ACT intervention consisted of
helping clients become aware of the costs of smoking, engage in clarification of values and
commitment to quitting smoking, and practice defusion, or seeing thoughts as thoughts rather
than as the cause of smoking. The intervention also targeted clients’ willingness to accept and
experience unpleasant situations, and to deal with lapses by getting back on track and resuming a
direction that was consistent with their values. The authors’ CBT intervention consisted of a
preparation phase in which participants received education on the health effects of smoking and
learned strategies to help them quit. In the quit phase, participants reduced the number of
cigarettes smoked and received instruction in cognitive and behavioral strategies to help them
cope with internal and external triggers. Finally, in the maintenance, phase participants learned
additional coping strategies to deal with triggers to smoke.
Hernandez-Lopez et al. (2009) observed promising long-term results for the ACT
condition compared to CBT. While the CBT condition showed a 13.2% intent-to-treat 30-day
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point prevalence of smoking cessation at 12-month follow-up, the ACT condition showed a
30.2% intent-to-treat 30-day point prevalence at 12 months. Further, the authors described the
ACT treatment to be as feasible as the CBT treatment in that participants in both conditions
participated in a majority of the sessions, rated the treatment as useful, stated satisfaction with
treatment, and practiced treatment techniques regularly. Similar findings were obtained by
(Gifford et al., 2011) in a randomized clinical trial of ACT and Functional Analytic
Psychotherapy (FAP) plus bupropion compared to bupropion alone. Gifford et al. observed
31.6% quit rates at 12 months for the combined treatment versus 17.5% for bupropion alone.
While the results from these three trials are promising, they both required significant
resources from clinicians and from participants. The two studies described next show promise for
briefer interventions delivered over the telephone. In a feasibility study, Bricker et al. (2010)
tested a five session, telephone-delivered ACT treatment for smoking cessation (please see
Appendix 3 for an intervention component list). The treatment was delivered over a three-month
period, with a total of 90 minutes of intervention time. Although this study employed a small
sample size (14 participants), the sample was diverse. It included ethnic minorities, individuals
with probable depression and anxiety, and individuals belonging to a low socioeconomic class
(e.g., 64% of participants were below the federal poverty level). The ACT counseling sessions
were delivered by a psychologist with expertise in ACT. The telephone contacts were brief (30
minutes for the first contact and 15 minutes for the rest of the sessions), and focused on teaching
both acceptance and commitment strategies. As described by Bricker et al. (2010), the
acceptance strategies involved:
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" (a) increasing one’s willingness to experience urges that [were] historically…
associated with smoking, (b) changing the function of smoking urges, and (c) responding
differently to smoking urges (e.g., noticing and not acting on urges).” (pp. 455).
Bricker et al.’s (2010) commitment strategies focused on helping participants identify
their values and take appropriate steps towards quitting smoking based on them. Participants in
this sample were receptive to the ACT intervention, with 100% stating they felt respected by
their counselor, 86% identifying the intervention as a good fit, and 93% saying that the
intervention helped them in their quit attempts. At the end of treatment, Bricker et al.’s therapists
delivered a mean of 3.5 telephone calls with an average of 82 minutes of total intervention time.
The investigators obtained higher cessation rates than those obtained by smoking cessation
counseling provided by telephone quitlines. While the quitline success rate is 12% (Stead,
Perera, & Lancaster, 2006), 43% of participants in Bricker et al’s ACT study had not smoked on
the day of the 20-day posttreatment interview, and 29% had not smoked in the 7 days prior to the
posttreatment interview. Cessation rates at 12-month follow-up were 29%. The authors
concluded that ACT approaches to smoking cessation delivered by telephone hold promise, but
that they should be investigated using well-powered randomized trials. Of note, a study
evaluating recordings of these phone sessions demonstrated that ACT could be delivered with
fidelity as a brief phone intervention (Schimmel-Bristow et al., 2012).
More recently, Bricker, Bush, et al. (2014) conducted a pilot study of a randomized trial
of ACT versus CBT for smoking cessation delivered over the telephone. Both study arms
consisted of five sessions as well as two weeks of NRT. This study demonstrated higher overall
quit rates at six months (31% for ACT and 22% for CBT), although these results were not
statistically significant. Further, the ACT intervention appeared to be particularly beneficial for
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smokers with depression (33% quit rates for ACT versus 13% for CBT), although this difference
was not statistically significant either, except for those participants who scored low on
acceptance of cravings at baseline (37% quit rates for ACT versus 10% for CBT). Importantly,
100% of study participants in the ACT condition said their treatment helped them to quit
smoking versus 83% for CBT.
In sum, the ACT studies described above have shown promising results in addressing
smoking, and they have tested a variety of different delivery formats, including in-person, group,
telephone, and web-based technologies. The ACT treatment in these studies appeared to be
particularly helpful in producing long-term outcomes (demonstrating superior cessation rates at
12-months). To our knowledge, ACT for smoking cessation has never been tested in a chronic
pain population, a group of smokers who have been understudied in smoking cessation research.
Barriers to Smoking Cessation among Chronic Pain Patients
Several barriers to smoking cessation among chronic pain patients have been identified in
the literature. From the patient’s perspective, these barriers include: difficulty in accessing care
(attitudinal barriers, transportation, architecture barriers, and logistical barriers) (Weaver et al.,
2011), use of smoking as a coping strategy for pain and distress (Hooten, Shi, et al., 2011), and
increases in the urge to smoke in some patients who use opioids (Hooten, Shi, et al., 2011). From
the physician’s perspective, lack of time (Hooten, Shi, et al., 2011), lack of knowledge about
smoking cessation (Hooten, Shi, et al., 2011), and concerns about the effects of abstinence on
pain (Ditre et al., 2011; Shi, Hooten, & Warner, 2011) were identified as barriers.
In spite of the detrimental effects of smoking on individuals with chronic pain, there have
been no rigorous randomized clinical trials demonstrating the effectiveness of smoking cessation
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interventions in this population (Ditre et al., 2011), although a pilot study (described earlier) by
(Hooten et al., 2014) has shown promising results. As described earlier, smoking among
individuals with chronic pain is a significant public health concern. Chronic pain patients often
have comorbid depression and anxiety, factors that are important to take into account when
addressing smoking in this population. Fortunately, research on smoking and pain has
significantly increased since the 1960s, with nearly 50 published studies in PubMed and 34 in
PsycINFO in 2008-2010 compared to fewer than 5 in 1963-1965 (Ditre et al., 2011). In addition,
as reviewed earlier, there have been a number of attempts to address smoking in this population,
including use of physician advice and cognitive behavioral approaches. Nonetheless, there is still
a need for research to be conducted in this population, especially regarding treatment.
Pilot Data
A pilot study was conducted using survey methodology to determine the smoking
cessation needs of the patients at the two multidisciplinary pain treatment centers from which
participants for the present study were recruited. Preliminary data analyses (N=97) revealed
current smoking rates to be 36%. Lifetime smoking prevalence (100+ cigarettes) was 62%.
Among current smokers, 72% reported smoking to manage pain (17% “always,” 33% “quite
often,” and 22% “seldom”). The top methods used by current smokers in previous quit attempts
were: “cold turkey” (21%), gradual cutting down (15%), electronic cigarettes (12%), nicotine
patches (10%), and Chantix (9%). Regarding readiness to quit, 66% of current smokers were
considering quitting smoking within the next 6 months, with 50% of these smokers planning to
quit in the next 30 days. Of the smokers, 87% reported openness to using smoking cessation
medications.
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When asked what type of provider they would like to help them quit smoking, the
smokers indicated a preference for a physician (21%) or a counselor/other mental health
professional (21%), followed by a registered nurse (17%), physical therapist (14%), or
pharmacist (14%). When queried about concurrent treatment targets in smoking cessation
interventions, patients wanted to focus on pain management (23%), depression (23%), anxiety
(19%), and the interaction between pain and smoking (15%). Of note, 40% of participants
reported living 40+ miles away from their respective pain treatment centers, and 100% of them
reported having access to a telephone. These preliminary data suggested that a majority of
smokers in these two settings wanted to quit smoking. Further, these patients expressed interest
in addressing pain, depression, and anxiety concurrently with smoking cessation. Given the
travel difficulties that many of these patients reported, a telephone-delivered intervention was
considered to be a more feasible option than either a group or in-person treatment format.
The Current Study
ACT has shown encouraging results for treating both chronic pain and smoking. Given
ACT’s theory that psychological flexibility is the underlying cause of psychopathology,
increasing psychological flexibility should lower psychological symptoms, including those
associated with depression and PTSD, as well as reduce smoking. Indeed, research suggests that
ACT has potential to lessen depression and pain-related anxiety (Wetherell et al., 2011), two
problems that may be causally linked to smoking among individuals with chronic pain. ACT
appears to be a promising intervention to effectively lower smoking rates among chronic pain
patients, a group that may have particular difficulty with quitting smoking according to research
evidence (Fishbain et al., 2007; Hooten et al., 2009). The current study examined the feasibility
and effectiveness of ACT for smoking cessation delivered over the telephone. Patients for the
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study were recruited from two multidisciplinary pain treatment centers in Missoula, MT. The
ACT intervention specifically addressed pain-related triggers for smoking and pain-related
anxiety.
The barriers identified above were targeted in our study in the following ways: We
addressed transportation and logistical barriers by providing the intervention over the telephone.
Smoking as a coping strategy for pain and distress was addressed by teaching patients alternative
coping skills. Regarding increased urges to smoke as a result of opioid use, our ACT intervention
taught patients to experience urges without having to react to those urges by smoking a cigarette.
Considering physician-related barriers, our telephone-delivered intervention by a trained
therapist freed up physician time, making it more likely that physicians would feel confident
advising patients to quit smoking because they had a person at their clinic to address their
patients’ smoking cessation needs. Finally, regarding concerns about the effects of abstinence on
pain from smoking, there is evidence suggesting that these concerns are unfounded (Shi et al.,
2011). Shi et al. (2011) found that quitting smoking was not linked to changes in pain among
adults 50 years or older. To address this concern, psychoeducation was provided to physicians
and other pain providers via presentations by research staff at the two multidisciplinary pain
treatment centers during the initial phase of our study, just prior to recruitment. In addition, all
participants in the study were educated about the relationship between pain and smoking.
As described earlier, multidisciplinary treatment centers can be ideal settings for treating
tobacco dependence among chronic pain patients. A telephone-delivered ACT intervention was
chosen over group and individual face-to-face sessions because it would utilize fewer clinic and
patient resources, potentially making it easier to implement the intervention at these settings if to
be found effective. Further, based on preliminary data,, a significant proportion of patients who
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attended the two multidisciplinary pain treatment centers in this study lived in rural areas and
reported difficulty traveling the long distances required to receive services. Telephone-delivered
interventions were chosen in an attempt to circumvent these barriers.

24

SMOKING CESSATION FOR CHRONIC PAIN PATIENTS

CHAPTER 2: HYPOTHESES

Primary
1. Participants receiving the intervention will experience higher cessation rates than those
achieved by participants receiving treatment as usual (TAU).
2. Participants receiving the intervention will demonstrate a greater reduction in number
of cigarettes smoked per day compared to those receiving TAU.
Secondary
1. Participants receiving the intervention will exhibit greater increases in psychological
flexibility from baseline to 3-months compared to TAU.
2. Participants receiving the intervention will demonstrate greater reductions in
depression scores from baseline to 3-months compared to TAU.
3. Participants receiving the intervention will demonstrate greater reductions in PTSD
scores from baseline to 3-months compared to TAU.
4 Participants receiving the intervention will evince greater reductions in pain-related
anxiety, pain interference, and pain intensity from baseline to 3-months compared to
TAU.
5. Changes in pain-related anxiety will predict smoking outcomes at 3 months.
6. Changes in psychological flexibility will predict smoking outcomes at 3 months.
7. Several indicators, including treatment satisfaction and number of sessions completed,
will suggest that the ACT intervention is feasible.
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CHAPTER 3: METHODS

Participants and Procedures
Participants were recruited through flyers and direct referrals from providers at two
multidisciplinary pain treatment centers.
Inclusion criteria were as follow:
1.

Screen positive for chronic pain (e.g., have experienced pain lasting 6 months or longer).

2.

Have smoked more than 100 cigarettes in their lifetime and currently smoke cigarettes.

3.

Have access to a telephone and agree to being contacted via telephone for 5 treatment
sessions and 3 follow-up sessions.

4.

Demonstrate a willingness to provide the telephone numbers of two contacts in order to
decrease the possibility of loss of follow-up retention and for verification of smoking status.

5.

Certify a desire/willingness to quit smoking.

Exclusion criteria included active psychosis, cognitive impairment, no access to a telephone, and
high risk for suicidality.
An a priori power analysis was conducted to determine the sample size for the present
study. Power analysis parameters were selected with the fact in mind that the study appears to be
the first to test an ACT intervention for smoking in chronic pain patients. The analysis set power
at 0.71, with an alpha of .10 and was run for the primary hypothesis that examined proportions of
patients in the study groups who quit smoking. The test value of 33% quit was used for the ACT
group based on the success rates of previous ACT interventions for smoking cessation (Bricker,
Bush, et al., 2014). The value of 12% quit was used for the TAU group, based on the standard
cessation rates for telephone-delivered smoking cessation provided by tobacco quitlines (Stead et
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al., 2006). The analysis indicated an overall target sample size of 50, with the goal of
randomizing 25 patients each to the experimental treatment and the control condition.
Participants were referred by providers from the two multidisciplinary pain treatment
centers, who handed flyers to their patients who smoked cigarettes (see Appendix 4 for a copy of
the flyer) and referred them to the smoking cessation researcher via a warm handoff. Researchers
explained the consent form to interested participants. Participants screened into the study
received a thorough explanation of all study procedures from the researcher. They were then
provided with an overview of the informed consent process and given the informed consent form
to read and sign if they agreed. They were also provided with a copy to take home. Those who
agreed to participate completed measures of chronic pain, smoking, depression, anxiety,
psychological flexibility and ACT processes, pain-related anxiety, alcohol and substance use,
and PTSD. There were only three patients who did not qualify for the study because they did not
smoke cigarettes, but rather chewed tobacco or smoked electronic cigarettes. These patients were
given information regarding the Montana Tobacco Quitline and were encouraged to call the
quitline for assistance in the quitting process.
Following determination of study eligibility and informed consent, the researchers
offered all study participants enhanced referral to the Montana Tobacco Quitline. Enhanced
referral included completion and submission of a faxed referral form to the Quitline. Patients
were then randomized to ACT or TAU through use of a random number table. Ultimately, 45
eligible participants agreed to participate in the study and were randomized; 24 participants were
assigned to the experimental intervention condition, and 21 were assigned to the control
condition. One participant in the control condition withdrew over the course of the study (see
diagram below for enrollment and follow-up information).
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Enrollment and Follow-Up Information

Assessed for eligibility (n= 50)

Excluded (n= 5)
♦ Not meeting inclusion criteria (n= 2)
♦ Declined to participate (n= 3)

Randomized (n= 45)

Allocation
Allocated to the TAU condition (n= 21)
♦ Received allocated Quitline treatment (n= 12)

Allocated to ACT intervention (n= 24)
♦ Received allocated intervention (n= 20)

♦

♦

Did not receive allocated intervention (n= 6)
Could not reach (n= 6)
♦ Quitline data unavailable (n= 3)

Did not receive allocated intervention (n= 4)
Could not reach (n= 3)
Declined intervention (n= 1)

Follow-Up (3-Months)
Lost to follow-up (n= 4)
Could not reach (n= 4)
Withdrew from study (n=0)

Lost to follow-up (n= 5)
Could not reach (n= 4)
Withdrew from study (n=1)

Analysis
Analysed (n= 20)
♦ Excluded from analysis due to study
withdrawal (n= 1)

Analysed (n= 24)
♦ Excluded from analysis (n= 0)
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Follow-up assessments were conducted at end of treatment (within 1 week), and at 3 and
6 months following the end of treatment. Assessments were conducted over the telephone by
clinical psychology graduate students who were blind to participants’ study conditions.
Psychological and pain measures were assessed at the 3 and 6-month follow-up interviews.
Confirmation of smoking status was obtained by obtaining collateral information from one of the
contacts provided at baseline or by using NicAlert’s saliva nicotine test. Saliva NicAlert has been
shown to predict self-reported smoking status with 100% sensitivity and 96% specificity
(Marrone, Paulpillai, Evans, Singleton, & Heishman, 2010). Only one participant in the study
chose the option of returning to the clinic to provide biological verification of smoking status,
but this person failed to come in to his perspective clinic to meet with the researcher for
provision of verification status. With the exception of this person, collateral information was
obtained for all other participants who quit.
A variety of incentives were used to support participants’ completion of baseline and
follow-up measures. Participants were given a small token purchased from a dollar store
following completion of baseline measures. Participants were offered $5 for the initial
assessment and for each follow-up assessment completed, for a total possible of $20. Participants
who completed all three follow-up sessions were entered in a raffle for a chance to win a $100
gift card at a grocery store of their choice. There was no compensation for the counseling
sessions. Follow-up assessments were completed via telephone or via mailed surveys.
Experimental Treatment Condition
Once the baseline measures were completed, the researcher gave a brief orientation about
the study procedures along with a binder of ACT handout materials for participants in this
condition to take home. The intervention was delivered over the telephone by two advanced
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clinical psychology doctoral students trained in ACT, and supervised by a licensed psychologist
with ACT training. The smoking cessation ACT sessions were delivered weekly for five weeks
over the telephone (see Appendix 5 for intervention details and Appendix 6 for participant
workbook).
The ACT intervention was adapted from Gifford et al. (2004), and it included
components from Hernandez-Lopez et al. (2009) as well as elements from an unpublished
protocol of ACT for the treatment of polysubstance abuse by Hayes, Wilson, Gifford, and Batten
(1998). Session 1 consisted of an introduction to the treatment and an assessment of internal and
external smoking triggers. Participants were prompted to talk about areas in their lives that have
been affected by smoking. An initial values assessment using The Matrix (Polk & Schoendorff,
2014) prompted participants to identify their values, understand what gets in the way of valuelinked behavior, and identify actions with potential to move them towards their values. Session 2
focused on helping the patient develop a behavioral plan for managing smoking triggers. Internal
triggers (especially depression, anxiety, and pain) were specifically addressed.
The researcher explained to patients how smoking and problems with quitting might arise
from efforts to control or avoid triggering experiences. Participants were encouraged to continue
to reflect on their values and to choose a quit date. Smoking reduction was strongly encouraged
in order to reduce withdrawal symptoms and to give patients an opportunity to practice resisting
smoking. Mindfulness skills were introduced and patients were encouraged to do a mindfulness
exercise on a CD that was provided to them along with their binder of handout materials upon
enrolling in the study. Session 3 focused on the ACT process of acceptance by use of metaphors,
helping clients practice experiencing cravings, and developing exposure hierarchies. Session 4
focused on the ACT processes of cognitive defusion, self as context, and committed action. In
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this session, clients were helped to identify and defuse cognitive triggers, see thoughts as
thoughts rather than as the cause of smoking, and see themselves as the context in which urges
and withdrawal symptoms take place while continuing to expose themselves to aversive
stimulus. Session 5 focused on the ACT value of commitment. Participants were encouraged to
notice when they were detouring from the direction they wanted to follow. They were advised to
simply get back to that direction regardless of the extent of any lapse (e.g., smoking one cigarette
or smoking for days). Relapse was explained as a part of the process of quitting.
Participants also received educational materials in their binder regarding information on
smoking cessation medication options. They were encouraged to check with their physicians
and/or the Quitline regarding their preferred choice of smoking cessation medication. The
meditation CD that participants received contained a number of guided meditations taken from a
pain workbook: “Living Beyond Your Pain” (Dahl & Lundgren, 2006). All sessions were
recorded for supervision purposes. As noted above, participants in this condition were also
referred for services provided by the Montana Tobacco Quitline, with researchers filling out a
fax referral form for the Montana Quitline to call them. This was done so participants in this
condition would be eligible to receive pharmacotherapy for quitting smoking. Services provided
by the Montana Tobacco Quitline are described below.
Control Condition
The control condition consisted of an enhanced treatment as usual (TAU) in which
participants filled out a fax referral form for the Montana Tobacco Quitline. Researchers faxed
the form, and the Montana Tobacco Quitline called the participants at the number they had
provided. According to the Montana Tobacco Use Prevention Program’s website by the Montana
Department of Public Health and Human Services (2014), the Montana Tobacco Quitline offers
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5 weekly sessions by a Quit Coach. Individuals wanting help with quitting are required to enroll
in the Quitline program, which offers a supply of nicotine patches, gum, or lozenges free of
charge for up 8 weeks. Chantix is also offered for a monthly co-pay of $50 per month for 3
months. Bupoprion is offered for a $5 copay per month for 3 months. The Quit Coach helps
smokers determine which medication may be the most appropriate for them. The enrollment
session lasts 10-15 minutes and callers get a personalized quit plan with 5 free sessions, as well
as educational materials for friends, family members, and providers (Montana Department of
Public Health and Human Services, 2014). Cessation rates for quitlines are 12% for counseling
and 14% for counseling in combination with NRT (Stead et al., 2006).
Measures
Demographics. Relationship status, age, gender, race/ethnicity, employment status,
education, and distance from the pain treatment center from which participants receive services
were assessed at baseline using open-ended questions.
Smoking Status. Smoking status was assessed at baseline, end or treatment, 3- and 6weeks by asking participants the number of cigarettes smoked in the past 24 hours, the number
of cigarettes smoked in the previous 7 days, and the number of cigarettes smoked in the past 30
days. Self-reported smoking is standard for interventions delivered over the telephone (Stead,
Hartmann-Boyce, Perera, & Lancaster, 2013).
Planning and Motivation to Quit. Participants were asked whether they were considering
quitting smoking in the next 6 months and whether they were planning to quit in the next 30
days. They were also asked to rank on a scale from 0-10 how motivated and how confident they
were in their ability to quit smoking.
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NRT Use. Participants were asked about their use of NRT or other smoking cessation
pharmacotherapy at baseline, end of treatment, and 3- and 6-weeks. We also obtained
information from the Montana Tobacco Quitline regarding whether they sent participants NRT
or Chantix.
Depression. The PHQ-8, given at baseline, and at 3- and 6-weeks, was used to assess for
depressive symptomatology. The PHQ-9 is a well-validated self-report measure of depressive
symptomatology (Kroenke, Spitzer, & Willimas, 2001) and it is commonly used in medical
settings. The PHQ-8 has been shown to be comparable to the PHQ-9 for identifying depressive
symptoms (Corson, Gerrity, & Dobscha, 2004; Kroenke & Spitzer, 2002). The PHQ-8 does not
include the question regarding thoughts that the individual would be better off dead, or of hurting
themselves, which was deemed a more appropriate measure given the telephone nature of the
current study and related difficulties in addressing suicidal ideation. On this measure,
participants reported the frequency of eight DSM-IV symptoms of major depression over the
past two weeks. The measure uses a four-point scale (0 = “not at all” - 3 “every day/nearly every
day”). Scores on the PHQ-8 range from 0-24. Higher scores indicate worse depressive
symptomatology. Scores of 10 or higher on the PHQ-9 identify a Major Depressive Episode with
high sensitivity and specificity (.88 to .93 for sensitivity, and 85 to .88 for specificity) (Kroenke
et al., 2001; Wittkampf et al., 2009). The cut-off score of 10 was applied to the PHQ-8 for the
present study to identify patients who were likely to have a current Major Depressive Episode.
Chronic Pain. Chronic pain was assessed at baseline by asking participants whether they
had experienced pain for a period of six months or longer. This is a conservative definition of
chronic pain, which as stated earlier, has been defined as pain lasting 3-6 months or longer (Task
Force on Taxonomy of the IASP, 1994).
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Pain-Related Anxiety. Pain-related anxiety was assessed at baseline, end of treatment, 3and 6-weeks and measured using the Pain Anxiety Symptoms Scale-20 (PASS-20). The PASS20 assesses fearful and anxious responses to pain in terms of both physical and cognitive
expressions, escape or avoidance behaviors, and fearful assessments of pain (McCracken &
Dhingra, 2002). The PASS-20 has demonstrated reliability and validity among people with
chronic pain (Ditre et al., 2013). The total score for the PASS-20 was used to measure painrelated anxiety, as it represents a comprehensive global composite of pain-related anxiety
(McCracken, Zayfert, & Gross, 1992). Higher scores are indicative of greater pain-related
anxiety and scores range from 0 to 100.
Pain. Additional pain variables were assessed at baseline, and at 3- and 6-weeks by use
of the Brief Pain Inventory Short From (BPI) (Cleeland & Ryan, 1994). The BPI is a
recommended measure of functioning (Dworkin et al., 2005) and assesses both pain severity and
pain interference. The two subscales of the BPI have shown adequate internal consistency
(Cronbach’s αs = .88 and .80 for pain interference for pain severity, respectively) (Wetherell et
al., 2011) and sensitivity to change in treatment (Tan, Jensen, Thornby, & Shanti, 2004).
Posttraumatic Stress Disorder. The Post-Traumatic Stress Disorder Check List-Civilian
Version (PCL-C) (Weathers, Litz, Herman, Huska, & Keane, 1993) was used to measure PTSD
symptomatology and severity at baseline, and at 3- and 6-weeks . This measure consists of 17
questions assessing DSM-IV symptoms of PTSD using a 5-point scale. Higher scores are
indicative of increased likelihood of PTSD diagnosis and greater PTSD symptomatology. A
cutoff score of 50 has been found to have a sensitivity of .90 and a specificity of .79 for
identifying PTSD in a non-Veteran population (Gardner, Knittel-Keren, & Gomez, 2012).
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Alcohol Misuse. The Alcohol Use Disorders Identification Test – Consumption (AUDITC) questions assessed alcohol misuse at baseline, and at 3- and 6-weeks. This measure addresses
frequency of alcohol consumption, number of drinks consumed in a single occasion, and
frequency of over-consumption. AUDIT-C scores range from 0-12, with higher scores
representing higher alcohol consumption. A cutoff score of four or more is recommended as a
screening threshold for alcohol misuse, with optimal specificity (.86) and sensitivity (.72) (Bush,
Kivlahan, McDonell, Fihn, & Bradley, 1998). Scores of 8-12 are indicative of severe alcohol
misuse and demonstrate associations with the lowest health status in research with Veterans
(Williams et al., 2010).
Treatment Satisfaction. Following Bricker et al. (2010) treatment satisfaction was
assessed at the end of treatment with four questions: Participants were asked 1) How satisfied
were you with the smoking cessation treatment you received? (0 = “not at all satisfied” – 5 =
“extremely satisfied”); 2) Did the treatment help you quit? (0 = “not at all” – 5 = “very much”);
3) Did you feel respected by your counselor? (0 = “not at all” – 5 = “very much”); 4) Was the
treatment a good fit for you? (0 = “not at all” – 5 = “very much”).
ACT Processes. Participants completed the Acceptance and Action Questionnaire (AAQII) (Bond et al., 2011) at baseline, end of treatment, 3- and 6-weeks . The AAQ-II is a measure of
experiential avoidance, acceptance, and psychological flexibility. This measure demonstrates
good reliability and validity evidence (Bond et al., 2011). In previous research, the AAQ-II has
been found to correlate with depression, anxiety, trauma symptomatology, medication taken for
pain, somatization, depression and anxiety about pain, and other mental health problems [see
Hayes et al. (2006) for a list of studies included in a meta-analysis]. The scale’s 10 items (e.g.,
my painful memories prevent me from having a fulfilling life, I worry about being unable to
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control my worries and feelings...) are rated on a scale from 1 = “never true” to 7 = “always
true.” Lower scores are indicative of higher psychological flexibility.
Statistical Analyses
All data were entered onto SPSS 17.0. Descriptive statistics were used to report
demographics, smoking, depression, PTSD, motivation to quit and confidence to quit at baseline.
Hypothesis 1 tested differences in cessation between the ACT and TAU groups at end of
treatment. This was examined with the Pearson’s Chi square test. Intent-to-treat analyses were
employed for this hypothesis, where all participants with missing data regarding smoking status
were counted as smokers. Participants were considered nonsmokers if they reported not smoking
any cigarettes in the past 7 days. Hypotheses 2-5 examined group differences over time in the
number of cigarettes smoked per day, psychological flexibility, depression severity, and PTSD
symptomatology. These hypotheses were tested with separate repeated measures analyses of
variance (ANOVA). The between subjects condition was ACT versus TAU. The within-subjects
condition was time, tested at end of treatment, 3 and 6 months-follow-ups.
A repeated measures MANOVA compared group differences regarding pain-related
variables: pain-related anxiety, pain interference, and pain intensity (Hypothesis 6). A linear
regression analysis examined whether reductions in pain-related anxiety or changes in
psychological flexibility predicted the number of cigarettes smoked per day at the three-month
follow-up (Hypotheses 7 and 8). The feasibility of the intervention (Hypothesis 9) was examined
using descriptive statistics indicating the number of telephone sessions completed and responses
to the treatment satisfaction questions. In addition, independent samples t-tests were used to
compare these variables between participants receiving the intervention and those accessing the
Quitline.
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CHAPTER 4: RESULTS
Demographic and baseline mental health and smoking characteristics:
Demographic and clinical characteristics are presented in Table 1 for the sample overall
(N=45) and for participants from the experimental (n=24) and control (n=21) groups. The mean
age was 48 (SD = 12.6). Sixty-two percent of participants were female and 38% male. In terms
of race and ethnicity, 89% identified as Non-Hispanic White, 4% as Native American or
American Indian, 2% as Asian, and 2% as other (more than one ethnic group or unknown
ethnicity). Regarding education status, 4% of our sample had some high school education, 40%
had a high school education, 49% had some college, and 7% had a college degree or higher. In
terms of marital status, 32% of our participants were single, 52% were married or living as
married, 7% were divorced, 2% were separated, and 5% were widowed. Only 22% of our
participants were employed, either part time or full time.
Every participant in the study was considering quitting within the next 6 months, and
87% stated planning to quit within the next 30 days. Overall, participants reported smoking
nearly 15 cigarettes per day at baseline, indicating moderate use (Wilson, Parsons, & Wakefield,
1999). Regarding motivation to quit, the mean motivation to quit was 8 (SD = 1.9) and the mean
confidence to quit was 7 (SD = 2.2). With regards to pharmacologic interventions, 56% of our
participants reported a history of using the nicotine patch, 36% had used a nicotine inhaler, 38%
reported trying Chantix in the past, 36% had used nicotine gum, 16% had used nicotine lozenges,
27% had tried Bupropion, and 38% reported a history of using electronic cigarettes.
Mental health concerns were prevalent: 40% of the overall sample scored at or above the
PHQ-8 cutoff score of 10, suggesting probable major depressive symptomatology. Regarding
PTSD, 18% of participants scored at or above the PCL-C score of 50, suggesting probable

37

SMOKING CESSATION FOR CHRONIC PAIN PATIENTS

PTSD, and 11% of our sample scored at or above the cutoff score of 4 on the AUDIT-C,
suggesting problematic alcohol use. There were no statistically significant differences between
the ACT and TAU groups at baseline on any demographic or clinical variables (see Table 1).
Table 1: Participant baseline descriptive information
Intervention
n=24 (53%)

Control
n=21 (47%)

Total
N = 45

p

49 (13.1)

47 (12.4)

48 (12.6)

0.67

Demographics
Age (Mean, SD)
Marital Status (n, %)
Married/co-habiting
Ethnicity (n, %)
Hispanic/Latino
Caucasian
American Indian
Asian
Other (n, %)

0.61
14 (60.9)

9 (43.0)

23 (52.3)
0.30

0 (0.0)
21 (87.5)
2 (8.3)
0 (0.0)
1 (4.2)

0 (0.0)
19 (90.5)
0 (0.0)
1 (4.8)
1 (4.8)

0 (0.0)
40 (89.0)
2 (4.4)
1 (2.2)
2 (4.4)

Gender (n, % Female)
Education (n, %)
Some High School
High School Diploma/GED
Some College
College Degree +

15 (62.5)

13 (62.0)

28 (62.2)

2 (8.3)
10 (41.7)
11 (45.8)
1 (4.2)

0 (0.0)
8 (40.0)
10 (50.0)
2 (10.0)

2 (4.5)
18 (40.9)
21 (47.7)
3 (6.8)

Employment (n, % employed)
Clinical & Smoking Characteristics

7 (29.2)

3 (15.0)

10 (22.3)

0.24

13.3 (8.1)
8.2 (1.9)
6.9 (2.3)
8 (33.3)
5 (20.8)
3 (12.5)

16.4 (10.2)
8.1 (2.0)
6.5 (2.2)
10 (47.6)
3 (14.3)
2 (9.5)

14.8 (9.2)
8.2 (1.9)
6.7 (2.2)
18 (40.0)
8 (18.0)
5 (11.1)

0.27
0.86
0.51
0.38
0.71
0.67

24.5 (13.1)
31.6 (21.5)
26.1 (5.7)
37.4 (14.3)

30.2 (17.0)
44.3 (26.4)
26.3 (7.1)
40.5 (15.9)

27.1 (15.1)
37.5 (24.5)
26.2 (6.3)
38.9 (15.0)

0.21
0.08
0.90
0.51

Cigarettes Per Day (Mean, SD)
Motivation to Quit (Mean, SD)
Confidence to Quit (Mean, SD)
Major Depressive Episode (n, % yes)
PTSD (n, % yes)
Alcohol Misuse (n, % yes)
ACT and Pain Characteristics (Mean, SD)
Psychological Flexibility
Pain-Related Anxiety
Pain Severity
Pain Interference

38

0.60
0.50

SMOKING CESSATION FOR CHRONIC PAIN PATIENTS

Attrition and Follow-Up Rates:
All participants in both study groups completed baseline measures. At the end of
treatment, 84% of all patients provided smoking status data, at a minimum, and 90% of TAU and
83% of ACT participants provided end or treatment data. The proportions of those who
responded at end of treatment did not differ between the two groups, X2 (1, N = 45) = 0.48, p =
.67, r = .10. At the 3-month follow-up assessment, we had at least smoking status data for 76%
of the sample (76% of TAU and 83% of ACT participants). There were no significant differences
in rates of response at the 3-month follow-up assessment either, X2 (1, N = 45) = 0.55, p = .71, r
= .11.
Cessation Rates:
Hypothesis # 1 was tested using intent-to-treat analyses, where all participants with
missing data were counted as smokers. At the end of treatment, four people (17%) in the
intervention condition had verified smoking 7-day point prevalence abstinence (confirmed by a
collateral contact), compared to only one person (5%) in the control condition. Although results
were not significant (X2 [1, N = 45] = 1.67, p = .22), r = .21, they were in the direction that was
hypothesized. At the 3-month follow-up assessment, two people in the intervention condition had
quit compared to only one in the control condition. These results were not statistically
significant, X2 (1, N = 45) = 0.23, p = 0.55, r = .08.
To explore the possibility of whether smoking cessation in the ACT group was related to
intensity of the intervention, we examined smoking abstinence among the 9 (38% of total) ACT
participants who completed all five sessions. In this subset of participants, 3 (33%) reported
abstinence at end of treatment. At 3-month follow-up, 2 (22%) of the completers reported
abstinence. Relative to the full sample of TAU patients, quit rates among ACT completers were
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significantly higher at end of treatment, X2 (1, N = 28) = 3.93, p = .08, r = .37, but not at 3-month
follow-up, X2 (1, N = 23) = .22, p = .58, r = .09.
Number of Cigarettes Smoked Per Day:
Hypothesis # 2 was tested using repeated measures ANOVA. At the one-week follow-up
assessment, there was a significant effect of time, F(1, 31) = 21.30, p < .05, ηp2 = .407,
indicating that smoking means decreased overall between baseline and end of treatment. There
was no significant effect of condition F(1, 31) = .10, p = .76, ηp2 = .003, suggesting no mean
differences between control and intervention participants. The interaction term, time × condition,
evidenced a trend toward significance F(1, 31) = 2.88, p = .10, ηp2 = .085. Figure 1 presents the
results graphically. As the graph illustrates, there was reduction in smoking over time for both
groups, with TAU participants demonstrating greater reductions.
We also examined smoking intensity relative to baseline at the 3-month follow up. In this
analysis, there was a significant effect of time, F(1, 28) = 5.80, p < .05, ηp2 = .172, suggesting a
reduction in smoking across the board. The main effect for group was not significant F(1, 28) =
.04, p = .84, ηp2 = .001, suggesting no mean differences between groups. The interaction term,
time × condition, was not significant, F(1, 28) = .36, p = .55, ηp2 = .013. Figure 2 presents these
results. The general reduction in smoking over time is evident in the Figure.
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Table 2. Smoking Cessation and Number of Cigarettes Smoke

N, %
Cessation Rates (n, %)
EOT1, Quit
EOT (Completers), Quit
Three-Month Follow-Up
Number of Cigarettes Smoked
Per Day (Mean, SD)
Baseline
End of Treatment
Three-Month Follow-Up
1

452 (100.0)
28 (62.2)
34 (75.6)

45 (100.0)
33 (73.3)
30 (66.7)

Intervention

Control

Total

p

4 (16.7)
3 (10.7)
2 (10.5)

1 (5.3)
1 (3.6)
1 (6.7)

5 (11.1)
4 (14.3)
3 (8.8)

0.22
0.08
0.55

14.8 (9.2)
9.82 (7.0)
10.57 (7.7)

0.27
0.10
0.84

13.3 (8.1)
11.06 (7.4)
10.75 (8.3)

16.4 (10.4)
8.05 (6.6)
10.36 (7.2)

EOT= End of Treatment. 2The sample size reported here denotes the total number of participants who provided

self-report data at End of Treatment. The analysis of quit rates assumed that nonrespondents were smokers.

Figure 1: Daily smoking baseline to end of treatment by group
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Figure 2. Daily smoking baseline to 3-month follow-up by group

Psychological Variables:
Separate mixed-design, repeated measures ANOVAs were used to assess differences in
psychological variables between the control and intervention condition from baseline to the
three-month follow up assessment (Secondary Hypotheses 1-3). Regarding psychological
flexibility, all effects are reported as significant at p<.05. There was a significant main effect of
time F(1, 27) = 5.51, ηp2 = .169, indicating that psychological flexibility scores increased
between baseline and three months. There was also a significant main effect for groups F(1, 27)
= 6.72, ηp2 = .812, indicating that psychological flexibility means differed based on condition.
The interaction term, time × condition was not significant, F(1, 27) = 0.18, p = .68, ηp2 = .007.
Figure 3 presents the results graphically. As can be seen, psychological flexibility means
increased over time, suggesting a reduction in psychological flexibility for patients in both
groups.
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Figure 3

Regarding depression scores, there was a significant main effect of time, F(1, 27) = 6.06,
p < .05, ηp2 = .183, indicating that depression scores increased between baseline and three
months. There was no significant effect of condition, F(1, 27) = 2.21, p = .15, ηp2 = .076,
suggesting no mean differences between control and intervention participants. The interaction
term, time × condition was not significant, F(1, 27) = 2.21, p = .15, ηp2 = .076. Figure 4 presents
the results graphically. As the graph illustrates, depression scores increased for both groups.
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Figure 4

Regarding PTSD scores, the main effect of time was not significant, F(1, 26) = 3.92, p =
.06, ηp2 = .131, indicating that PTSD scores did not significantly increase between baseline and
three months. There was no significant effect of condition F(1, 26) = 2.97, ηp2 = .103, suggesting
no mean differences between the control and the intervention conditions. The interaction term,
time × condition was not significant F(1, 26) = .12, p = .74, ηp2 = .004. As illustrated in Figure
5, PTSD scores increased fairly equally for both groups from baseline to 3-months.
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Figure 5

Pain Variables:
A repeated measures MANOVA was used to test Secondary Hypothesis # 4. This
analysis revealed no significant effect of time on the composite variable of pain-related anxiety,
pain severity, and pain interference, F(3,22) = 0.48, p = .70, ηp2 = .062. There was no significant
main effect for condition on the composite pain variable, F(3,22) = 1.43, p = .26, ηp2 = .163. The
interaction term, time × condition was nonsignificant F(3,22) = 1.64, p = .21, ηp2 = .183.
Predictors of Smoking:
Secondary Hypotheses # 5 and 6 were tested using a multiple regression analysis that
tested whether changes in pain-related anxiety or in psychological flexibility predicted number of
daily cigarettes smoked at 3-month follow-up. The results of the regression were nonsignificant
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(R2 = .07, F(2,26)=.93, p = .41), indicating that neither changes in psychological flexibility nor
changes in pain-related anxiety significantly influenced the number of cigarettes smoked per day
at the three-month follow-up (see Table 4).
Table 3. Concurrent predictors of number of cigarettes smoked

B
Constant
Pain-Related Anxiety Changes
Psychological Flexibility Changes

β

SE B
9.87

1.63

.04

.09

.09

-.20

.16

-.25

2

Note: R = .07, p = .41

Feasibility of the Intervention:
Regarding Secondary Hypothesis # 7, participants in the intervention condition
completed an average of 3.1 out of 5 sessions (SD = 1.9). The majority of participants (83%)
completed at least one session of ACT, with 2 participants (8%) completing one session, 5
participants (21%) completing two sessions, 2 participants (8%) completing three sessions,
another 2 (8%) completing four sessions, and 9 participants (38%) completing all five sessions.
Data from the Quitline for the overall sample indicate that participants completed an
average of 1.4 sessions (SD = 1.7) through the Quitline. 10 participants (22%) completed one
session, 2 participants (4%) completed two sessions, 7 participants (16%) completed three
sessions, 3 participants (7%) completed four sessions, 2 participants (4%) completed five
sessions, and 1 participant (2%) completed six sessions. Regarding NRT/pharmacotherapy, 17
participants (38%) were mailed NRT, and 1 participant (2%) was mailed Chantix by the Quitline.
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Treatment Satisfaction. Independent samples t-tests examined differences in treatment
satisfaction between conditions. There were no significant differences for treatment satisfaction
rankings between the control and intervention conditions t(32) = 0.69, p = .50, or in rankings of
feeling respected by the counselor for the control and intervention conditions; t(17.24) = -1.35, p
= .19. Participants in the control condition reported significantly higher rankings than
participants in the intervention condition regarding the degree to which their treatment helped
them quit t(32) = 2.16, p = 0.04. In addition, there were significant differences for rankings of
whether the treatment was a good fit for them between participants in the control condition and
participants in the intervention condition t(30) = 2.37, p = 0.02. In both cases, patients in the
control condition provided more favorable ratings than patients in the intervention condition (see
Table 4).
To reduce the possibility of spurious treatment satisfaction data provided by participants
who did not engage in any of the counseling sessions, we conducted a follow-up analysis using
only participants who had completed at least one session in either condition. These data showed
higher (although not statistically significantly so) rankings for the intervention condition for
satisfaction with treatment (M = 3.85, SD = 1.51) than for the TAU condition (M = 3.45, SD =
1.80), t(23) = -0.61, p = 0.55, as well as higher rankings for feeling respected by their counselor
in the intervention condition (M = 4.93, SD = 0.27) versus the TAU condition (M = 4.36, SD =
1.50), t(23) = -0.14, p = 0.18. The rankings for treatment fit for the intervention (M = 3.46, SD =
1.61) versus the TAU condition (M = 4.09, SD = 1.51), t(22) = 0.98, p = 0.34, and the degree to
which the treatment helped them quit for the intervention (M = 2.07, SD = 2.30) versus the TAU
condition (M = 3.18, SD = 2.18), t(23) = 1.22, p = 0.23 were no longer statistically significantly
different, but they were still higher for the TAU condition.

SMOKING CESSATION FOR CHRONIC PAIN PATIENTS

48

Table 4. Feasibility of the Intervention

N

Intervention

Control

Total

Feeling Respected by Counselor

32

4.9 (0.2)

4.5 (1.2)

4.7 (0.9)

0.19

Satisfaction with Treatment

32

3.5 (1.9)

3.9 (1.6)

3.7 (1.7)

0.50

Treatment was a Good Fit

32

3.0 (1.9)

4.4 (1.3)

3.7 (1.7)

0.02

Treatment Helped in Quitting

30

1.7 (2.2)

3.3 (2.1)

2.5 (2.3)

0.04

3.1 (1.9)
1.4 (1.8)

N/A
1.8 (1.6)

N/A
1.6 (1.7)

0.47

p

Treatment Satisfaction Variables (mean, SD)

Number of Sessions Completed (mean, SD)
ACT Treatment
Quitline Counseling

Exploratory Analyses:
We were interested in exploring whether NRT/pharmacotherapy for smoking cessation
rates differed by condition and in examining whether there were group differences in motivation
or confidence to quit at the end of treatment and at the 3-month follow-up assessments.
Regarding NRT/pharmacotherapy for smoking cessation, when examining only participants who
had completed at least 1 session with the Quitline, the proportions of participants using NRT was
significantly higher for the TAU condition (85%) than for the intervention condition (30%) X2
(2, N = 33) = 11.26, p = .004, r = .58. When examining the overall sample, these results were no
longer significant X2 (2, N = 39) = 4.60, p = .10, r = .34.
Mean differences in motivation to quit were tested using repeated measures ANOVA. At
the end of treatment, there was no significant effect of time, F(1, 35) = 2.33, p = .14, ηp2 = .062,
indicating that motivation means did not decrease significantly between baseline and end of
treatment. There was no significant effect of condition F(1, 35) = .29, p = .59, ηp2 = .008,
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suggesting no mean differences between control and intervention participants. The interaction
term, time × condition, was nonsignificant F(1, 35) = 1.24, p = .27, ηp2 = .034. We also
examined motivation to quit relative to baseline at the 3-month follow up. In this analysis, there
was a significant effect of time, F(1, 28) = 12.46, p < .05, ηp2 = .308, suggesting that motivation
means reduced across the board. The main effect for group was not significant F(1, 28) = 1.76, p
= .20, ηp2 = .059, suggesting no mean differences between groups. The interaction term, time ×
condition, was not significant, F(1, 28) = .36, p = .55, ηp2 = .013. Figure 6 presents these results
graphically, illustrating the reductions in motivation means for both groups between baseline and
3 months.
Figure 6
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Mean differences in confidence to quit were also tested using repeated measures
ANOVA. At the end of treatment, there was no significant effect of time, F(1, 35) = .36, p = .55,
ηp2 = .010, indicating that confidence means did not significantly differ between baseline and
end of treatment for the overall sample. There was no significant effect of condition F(1, 35) =
3.18, p = .08, ηp2 = .083, suggesting no overall mean differences between control and
intervention participants. The interaction term, time × condition, was significant F(1, 35) = 4.54,
p = < .05, ηp2 = .115, indicating that confidence means decreased for intervention participants
while they increased for the TAU participants at the end of treatment. We also examined
confidence in quitting relative to baseline at the 3-month follow up. In this analysis, there was
not a significant effect of time, F(1, 28) = 3.25, p = .08, ηp2 = .104, suggesting that confidence
means did not significantly differ between baseline and end of treatment for the overall sample.
The main effect for group was not significant F(1, 28) = .42, p = .52, ηp2 = .015, suggesting no
mean differences between groups. The interaction term, time × condition, was not significant,
F(1, 28) = .29, p = .60, ηp2 = .010. Figure 7 illustrates these results, showing a trend for reduced
confidence means for both groups between baseline and 3 months.
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CHAPTER 5: DISCUSSION

The literature suggests that chronic pain patients who smoke may have particular
difficulty quitting (Fishbain et al., 2007; Hooten et al., 2009). Our results are consistent with
these findings, with only 9% of our overall sample successfully quitting at the three-month
follow-up assessment. Participants in the ACT condition had higher verified smoking 7-day
point prevalence abstinence (confirmed by a collateral contact) at the end of treatment
assessment (15% for ACT versus 5% for TAU), although these results were not statistically
significant. However, when only intervention completers (those who completed all 5 sessions of
ACT) were examined against participants in the TAU condition, these results were statistically
significant. This exploratory analysis suggested that the ACT intervention, as it was designed,
may hold promise for those smokers with chronic pain who have the capacity to complete the
full course of treatment. At the 3-month follow-up assessment, two participants in the ACT
condition (11%) had quit smoking versus only one in the TAU condition (7%). Overall, our
results suggest that ACT may have potential to address smoking among individuals with chronic
pain. Further study is clearly needed to identify factors that supported treatment completion for
some patients but not for others. Though our results suggest some potential promise for ACT,
these data need to be understood in light of the very small numbers of patients overall who quit.
Ultimately, because the current study was proposed as a preliminary pilot study of the
effectiveness of ACT in smoking cessation among chronic pain patients, our sample size was
relatively small.
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To our knowledge, this is the first study to test whether Quitline services can meet the
needs of chronic pain patients. Tobacco Quitlines offer five smoking cessation counseling
sessions and NRT, free of charge to people who enroll in the service. The 12% quit rates (Stead
et al., 2006) reported at the population level make a large impact in reducing smoking-related
morbidity and mortality. Cessation rates in the present study were lower overall than the Quitline
cessation rates in the general population, and even lower among participants in the control
condition receiving the Quitline-only treatment. In our study, at end of treatment, the ACT +
Quitline group achieved 17% cessation, a rate that approximated Quitline-only rates reported for
the general population. Cessation dropped from 17% at end of treatment to 11% at 3-month
follow-up in the ACT group, suggesting that maintenance of cessation is an important issue to
address. Although the reasons behind the relatively low quit rates in the present study are
impossible to know for certain, several possibilities are described below, including the high rates
of psychological disorders, the shorter duration of our intervention, or the persistent chronic pain
experienced by our patients. Collectively, these possibilities suggest that pain clinic patients may
need more specialized and/or more intensive smoking cessation assistance than patients drawn
from other settings.
When comparing our quit rates and nonsignificant findings in the control and intervention
conditions to those in other studies using ACT for smoking cessation, it is worth noting that
these studies failed to find significant differences until the 12-month follow-up assessment. The
pilot study by Bricker et al. (2010), finding a 7-day point cessation prevalence of 29% at the 20
day posttreatment interview, did not have a control condition and the sample was very small
(only 14 participants). Further, recruitment in their study was conducted via free advertisements
and news media that included: Craigslist.com, Backpage.com, The Stranger, and The Dallas
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Observer. It is possible that the positive results reported by Bricker et al. (2010) were attributable
in part to a self-selection bias. In other words, those who took the time to respond and call the
study number may have had higher intrinsic motivation for quitting than the participants in our
study who were handed off by their chronic pain providers.
In addition, despite our emphasis on the voluntary nature of participation in our study, it
is possible that our participants may have felt a slight social pressure to tell their physicians they
were willing to quit smoking and to participate in the study, perhaps giving us slightly inflated
baseline motivation rankings. Nevertheless, our intervention average number of calls of 3.1 was
just slightly lower than that of Bricker’s of 3.5, suggesting that even if there was a slight social
pressure to participate in the study, these patients still engaged in the telephone counseling
sessions, even without compensation. This is important, considering that engagement in smoking
cessation treatment is associated with a higher likelihood of abstinence, with a higher number of
sessions producing better outcomes, especially if combined with medication (U.S. Department of
Health and Human Services, 2008).
Another possible explanation for our lower cessation rates relative to Bricker et al.’s
(2010) study might be the fact that our intervention was delivered over a 5-week period rather
than over a 3-month period. The longer period of time between sessions in their study may have
provided additional time for patients to rehearse skills and problem-solve. Our 5-session
intervention delivered over 5 weeks may not have provided ample rehearsal and problem-solving
opportunities. However, given the nature of our study, and our limited resources, delivering the
intervention over 5 weeks was deemed in advance to be more feasible.
In the ACT for smoking cessation studies by Gifford et al. (2004) and Hernandez-Lopez
et al. (2009), there appeared to be a ‘sleeper effect’. Although these interventions involved
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significant time and substantial treatment resources, significant differences between groups did
not emerge until the 12-month follow-up assessment. This ‘sleeper effect’ is similar to that found
in motivational interviewing (White, Mun, Pugh, & Morgan, 2007), and although it is not
immediate, the long-term outcomes are promising and quite possibly more likely to endure. For
the present study, 6-month follow data collection is ongoing. Unfortunately, 12-month follow-up
data will not be collected. Future studies should assess whether ACT for smoking cessation
treatment for a chronic pain population confers success in long-term follow-up rates.
The findings regarding smoking intensity showed a reduction in smoking over time for
both groups, suggesting that addressing smoking in our two multidisciplinary pain settings was
beneficial. Ultimately, this good news suggests that substantial declines in smoking intensity are
achievable among patients with chronic pain and substantial psychiatric comorbidities. This
finding is also consistent with the U.S. Department of Health and Human Services' (2008)
Clinical Practice Guidelines for Treating Tobacco Use and Dependence, which recommends
addressing tobacco use in health settings.
Reductions in smoking were evident in our study, but outright cessation was less
common. The difficulty in moving from reduction to cessation may have been a function of
psychiatric complexity or the high prevalence of depression, PTSD, and alcohol misuse in our
sample. Recall, for example, that 40% of our participants likely met diagnostic criteria for Major
Depressive Disorder, 18% met criteria for PTSD according to the PCL-C, and 11% reported
alcohol misuse on AUDIT-C. Another possibility for the low quit rates may be that chronic pain
patients require a higher level of care for smoking cessation than smokers without concomitant
psychological disorders. They may require a higher number of sessions, and/or combined
formats (e.g., in person, telephone, group, etc.), such as the intervention performed by Hooten et
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al. (2014) described earlier in this paper. The U.S. Department of Health and Human Services'
(2008) Clinical Practice Guidelines for Treating Tobacco Use and Dependence strongly
encourage health providers to overcome their reluctance to address smoking cessation in
populations with psychological disorders, given patients’ high rates of smoking and the evidence
suggesting that they want to and are able to quit smoking if given appropriate smoking cessation
care.
There is evidence that smoking among individuals with depression is associated with
complex health circumstances in physical and mental health domains (Lombardero et al., 2014).
These circumstances include higher depressive symptomatology, higher likelihood of presence
of comorbid PTSD, higher alcohol consumption, worse overall mental health status, more
medical comorbidities, and lower levels of social support (Lombardero et al., 2014). If smoking
is not addressed among individuals with chronic pain and psychological disorders, it is likely that
their health will continue to worsen as smoking continues, and their depression and pain remain
constant or increase in severity. Fortunately, the evidence observed in the present work suggests
that many smokers with chronic pain, like smokers with psychological disorders, are considering
quitting smoking and are able to cut down. It is imperative to find optimal interventions for this
population so that their smoking cessation needs can be met. For example, in the treatment of
smokers with mental health conditions, the evidence suggests that integrating tobacco treatment
in mental health settings can be more effective than assessment of smoking followed by referral
to separate smoking cessation clinics.
Indeed, McFall et al. (2007) studied a randomized tobacco treatment study among
patients with PTSD. Their results showed a 5-fold increased likelihood of cessation at 2, 4, 6,
and 9 months in smokers with PTSD by providing integrated smoking cessation treatment.
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Further, McFall et al.’s (2010) second study of integrated smoking cessation treatment among
PTSD patients demonstrated that integrated care can improve long-term (18-months) smoking
abstinence rates by more than double compared to referring patients to smoking cessation clinics.
Although our study integrated tobacco treatment in a pain setting, the researchers were not
clinical staff treating ongoing patients, and our treatment was short in duration relative to McFall
et al.’s (5 weeks versus 3 months). It is possible that a similar study, integrating tobacco
cessation care provided by psychologists treating their ongoing clients in pain settings might
result in better patient engagement and better outcomes. Other studies of tobacco treatment
integration among smokers with psychological disorders have also shown promising results. A
stepped-care intervention tested by Hall et al. (2006) and tailored to patients recruited from
outpatient mental health treatment considered readiness to quit, provided computerized
motivational feedback, and also provided an optional 6-session psychological counseling and
pharmacological tobacco cessation treatment. This intervention produced positive outcomes,
showing significantly higher quit rates than for the group receiving brief contact. It is possible
that an ACT intervention that includes a motivational enhancement component may prove
effective in chronic pain settings.
Understanding the links between smoking and mental health can be important in
addressing smoking among chronic pain patients, and in interpreting the lower cessation rates
found in our study as well as in other studies of smoking cessation among chronic pain patients
(e.g., Hooten et al., 2009). A number of mental health conditions associated with smoking, such
as mood disorders, anxiety disorders, personality disorders, and substance use disorders have
been shown to predict persistent nicotine dependence among adults in the United States (R. D.
Goodwin, Pagura, Spiwak, Lemeshow, & Sareen, 2011). Without treatment, the predicted
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probabilities of quitting smoking in primary care have been found to be lower for patients with
alcohol, drug, or mental disorders (6.0%) than for smokers without these disorders (10.5%)
(Ong, Zhou, & Sung, 2011). Research has shown, for example, that compared to non-depressed
smokers, depressed smokers are less likely to stop smoking and more likely to experience
smoking relapse (Kinnunen, Doherty, Militello, & Garvey, 1996; Niaura et al., 2001). However,
it is important to keep in mind that these smokers are still motivated to quit, and that they have
been shown to successfully quit with appropriate interventions, as described above.
The increase in depression scores from baseline to the 3-month follow-up in the present
study is consistent with other studies examining psychiatric symptoms during smoking cessation
(Aubin, 2009; Aubin, Rollema, Svensson, & Winterer, 2012) and could be partially explained by
the similarities between withdrawal symptoms and symptoms of depression (Hall & Prochaska,
2009). Additionally, in our sample, indicators of multiple aspects of pain persisted from baseline
to end of treatment and 3-month follow-up. The persistence of pain may also have played a role
in the increase of depression symptoms in the present sample. The interactive relationship
between pain and depression, for example, is documented in the literature (Arnow et al., 2006;
Atkinson et al., 1991).
We also found decreases in psychological flexibility over time in the present study. This
may have been related to the observed increases in depression and/or pain persistence.
Psychological flexibility correlates highly with depression, negative mood, anxiety, and stress,
for example (Hulbert-Williams & Storey, 2015). With these possibilities in mind, it is important
to note that the evidence drawn from studies of psychiatric patients highlights that quitting
smoking does not worsen psychiatric symptoms (Hall & Prochaska, 2009; Prochaska, Hall,
Delucchi, & Hall, 2014). Further, a study of tobacco dependence treatment initiated in inpatient
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psychiatry demonstrated lower psychiatric rehospitalization rates among participants who had
quit smoking than among those who continued to smoke (Prochaska et al., 2014), suggesting
possible protective effects of quitting smoking. In our study, the increase in depression did not
significantly differ by condition, indicating that both groups experienced similar levels of
increases in symptomatology.
The U.S. Department of Health and Human Services' (2008) Clinical Practice Guidelines
for Treating Tobacco Use and Dependence among psychiatric patients highlight the potential
beneficial effects of antidepressants, particularly Bupropion SR and Nortiptyline in increasing
long-term smoking cessation rates among people with a past history of depression, based on
studies comparing antidepressants to placebo. These guidelines also emphasize that there is not
enough evidence yet to determine whether addressing psychiatric symptoms in a smoking
cessation intervention is more beneficial than standard tobacco cessation treatments. A reason for
the lack of knowledge about smoking cessation among psychiatric patients is that most of the
smoking cessation trials excluded participants with active depression (Gierisch, Bastian,
Calhoun, McDuffie, & Williams, 2010). However, new studies in this domain show promise in
considering mental health status in smoking cessation efforts. Smoking cessation interventions
tailored to the specific needs of individuals with mental illness demonstrate better outcomes than
non-tailored treatments, such as higher cessation rates and prolonged abstinence (Hayford et al.,
1999; Patten, Martin, Myers, Calfas, & Williams, 1996).
In a study of smoking cessation among college students with depression, Schleicher,
Harris, Campbell, and Harrar (2012) found that depressed smokers in a mood-oriented group
treatment for smoking were more likely to reduce smoking intensity by 50%. These participants
also evidenced a greater increase in smoking reduction confidence compared to participants in an
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active control condition. Given the high rates of depression among chronic pain patients, it seems
relevant to address and monitor depression during smoking cessation. To our knowledge, our
study is the first to address both depression and pain as internal triggers for smoking, but a longer
treatment duration may be required to obtain more optimal results.
Considering research suggesting certain characteristics that may contribute to the
maintenance of smoking behavior among chronic pain patients, we were interested in examining
changes in pain-related anxiety (Ditre et al., 2013), and changes in psychological inflexibility, an
underlying contributor to psychopathology and suffering according to ACT (Harris, 2009) as
possible predictors of smoking. Our insignificant findings may be due to our small sample size,
or to the very small changes in pain-related anxiety found among our chronic pain patients.
Future studies with larger samples should examine explicitly the contributions of these variables
to smoking quantity or to the likelihood of successful smoking cessation.
Regarding our pain variables, we did not find significant changes from baseline to the
three-month follow-up assessment, nor did we find changes by condition. These findings
suggested that pain-related anxiety, interference, and severity were not affected by addressing
smoking or by attention to pain during the intervention. These findings also suggest that these
pain indicators were persistent among the smokers in our sample, despite whatever treatment
they received from their pain clinics. These observations are consistent with Hooten et al.’s
(2014) findings that smoking status did not affect pain-related treatment outcomes. According to
Ditre et al.’s (2011) paper investigating the relationship between smoking and pain, “there have
been no published studies that examined how the engagement or completion of treatment for
chronic pain may influence smoking-related factors such as the urge to smoke, smoking
behavior, motivation to quit, or cessation- related outcomes” (p. 18). This is an area in which
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future research may be helpful. Our study provides additional evidence that smoking reduction
does not appear to negatively affect pain, which can be helpful psychoeducation to provide to
patients who smoke in an effort to cope with pain.
Regarding the feasibility of the intervention, participants in both conditions reported
feeling respected by their counselors and being satisfied with their treatment. Participants in the
Quitline condition, however, reported higher ratings in the helpfulness of the treatment and in the
degree to which the treatment was a good fit for them than participants in the ACT condition,
although these differences were not significant when examining rankings from people who had
completed at least one session of either TAU or ACT. Although these findings seem to suggest
that participants found the TAU condition to be a better fit and to be more helpful in the process
of quitting, it is important to remember that participants in both conditions had contact with the
Quitline. These findings may reflect confusion about having two slightly different treatments, or
feeling overwhelmed by receiving more phone calls than the standard once-a-week session
provided by tobacco Quitlines.
It is also quite possible that some patients in the ACT condition were poor fits for the
intervention, given their lower rankings of fit and helpfulness in quitting. In spite of the lower
rankings in these two categories, participants reported overall satisfaction with both treatments,
suggesting that pain patients are amenable and generally satisfied with interventions delivered
over the telephone. Future studies should examine patient preferences for smoking cessation.
Some of the existing evidence in this domain suggests that chronic pain patients prefer a group
format while in an interdisciplinary pain program as well as follow-up support including social
networks, emails, or phone calls from their counselors (Hooten, Vickers, et al., 2011). We chose
not to do a group intervention in our study due to practical barriers, such as transportation, that
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limited our ability to recruit and maintain the high number of patients needed for the current
study.
Of note, based on our exploratory analyses, participants in the TAU condition used NRT
at higher rates than participants in the ACT condition. Although participants in the ACT
condition were encouraged to pursue NRT/pharmacotherapy for smoking cessation, it is possible
that they found it more inconvenient to do this via another outlet (the Quitline) than if we had
had the ability to provide these resources ourselves. The higher rates of NRT/pharmacotherapy
use found in the TAU condition could explain the higher reduction in number of cigarettes per
day found in this condition compared to the ACT condition as well as the end of treatment higher
rankings in confidence to quit smoking. Although it is impossible to determine if our findings
would have been different had we had the resources to provide NRT/pharmacotherapy to
participants in the ACT condition, future studies comparing ACT to CBT should continue to
provide NRT/pharmacotherapy to participants, as this has been found to increase the likelihood
of success in smoking cessation (U.S. Department of Health and Human Services, 2008).
This study includes several important limitations. First, our sample consisted
predominantly of middle-aged, predominately high-school educated, Caucasian patients, with
high rates of probable depression and probable PTSD. Any generalization of the present findings
to other patient populations ought to be done with caution. At the same time, we were
specifically interested in chronic pain patients and the high rates of depression and PTSD found
in our sample are consistent with those found among chronic pain patients (Arnow et al., 2006;
Atkinson et al., 1991; Dersh et al., 2002; Roy-Byrne et al., 2004). Our study provides valuable
information about chronic pain patients who are mostly Caucasian and from rural areas of the
country. Other studies should recruit a more ethnically diverse sample, and in urban areas.
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A second limitation is that the nature of the feasibility study limited our ability to make
definitive conclusions regarding the mechanisms underlying tobacco use among chronic pain
patients and limited our ability to know with certainty whether the ACT intervention was
effective. However, this study opens the door for future studies examining the effectiveness of
ACT for smoking cessation in this population. A third limitation is that our study did not follow
participants to obtain 12-month cessation outcomes. This would have allowed tracking of longterm ‘sleeper’ effects that have emerged in other studies of ACT for smoking cessation and other
studies using Motivational Interviewing that found significant differences at 12- or 18-month
follow up assessments (Gifford et al., 2004; Hernandez-Lopez et al., 2009; White et al., 2007).
Tracking patients for 12 -months in the present study was simply not possible. Future studies
testing ACT in this population could address this limitation by including longer-term follow-ups.
In conclusion, our study provides preliminary evidence of the potential effectiveness of
ACT for smoking cessation in a chronic pain population, a population with characteristics (e.g.,
high rates of depression, PTSD, and alcohol misuse) that can complicate smoking cessation
efforts. Our results suggest that it is feasible to address smoking in some multidisciplinary pain
treatment settings, and that these patients are generally satisfied with phone-based interventions.
The overall low rates of smoking cessation in our study suggest that chronic pain patients may
need increased attention to smoking, potentially including other formats such as group and
individual therapy, provision of NRT/pharmacotherapy, and/or increased number of smoking
cessation sessions. Future studies in this area are desperately needed in order to help address a
significant public health concern: smoking among chronic pain patients.
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Appendix 11
Gifford et al. (2004) Intervention Components (pp. 695-696)
"1. Internal versus external triggers. Therapists helped clients identify their internal triggers,
i.e., thoughts, feelings, and physiological sensations associated with smoking. Therapists
described the role internal triggers play in smoking and their relevance to the quitting process.
2. Problems with control efforts. Therapists helped clients identify that efforts to control or
avoid internal experience are linked to smoking and to problems with quitting. Experiences from
participants' smoking histories and history of smoking attempts were considered (e.g., drawing
out the success or failure of previous cessation strategies). This section of the ACT protocol was
designed to help clients identify control-based strategies and enhance motivation to try
acceptance-based strategies instead.
3. Values, goals, and barriers. Therapists helped clients clarify their values, define goals related
to their values, and identify barriers to achieving their goals. Goals were defined as specific
behavioral tasks related to quitting smoking. Barriers were defined as
thoughts/feelings/sensations that derail efforts to perform these tasks. Clients were asked to
identify the internal experiences most likely to function as barriers (i.e., the thoughts, feelings
and sensations most likely to trigger smoking or attrition from treatment).
4. Acceptance and willingness. Therapists provided the rationale for approaching/accepting
previously avoided internal stimuli, and for the skills training format. Through exercises and
metaphors, clients identified that there is not an intrinsic link between feelings and actions and
that the presence of aversive internal experiences in and of themselves does not constitute a
threat. (Clients had multiple programmed opportunities to experience feelings and thoughts fully
without acting on them.) The purpose of this component was to reduce motivation for avoidant
behavior and to increase tolerance for discomfort.
5. Mindfulness skills. Clients participated in experiential exercises designed to develop a safe
and consistent perspective from which to observe and accept all changing inner experiences.
Mindfulness techniques were incorporated during this phase in order to enhance awareness of
problematic stimuli and also to expand awareness of alternative features of their experience and
environment in order to promote cognitive and behavioral flexibility.
6. Graduated exposure. Therapists helped clients establish individualized exposure hierarchies.
During these exposure sessions clients experienced increasing levels of withdrawal symptoms
and aversive internal states. Therapists provided support and reinforced participants' contact with
their previously avoided inner experiences. The goal of this treatment component was to alter the
avoidant and smoking-related stimulus functions of internal stimuli through extinction and to add
stimulus functions linked to alternative responses.
7. Scheduled smoking. If requested by participants as part of their graduated exposure
hierarchies, therapists provided smoking schedules according to algorithms based on current
client smoking and hours of wakefulness. Scheduled smoking increases the latency between the
1

The intervention components by Gifford et al. (2004) (pp. 695-696) described here are
reproduced verbatim from the source: Gifford, E. V., Kohlenberg, B. S., Hayes, S. C.,
Antonuccio, D. O., Piasecki, M. M., Rasmussen-Hall, M. L., & Palm, K. M. (2004). Acceptancebased treatment for smoking cessaion. Behavior Therapy, 35(4), 689-705.
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stimuli associated with smoking and the occurrence of smoking responses. These structured
periods of delayed responding provided windows in which to practice identifying and responding
differently to withdrawal symptoms/internal triggers outside of the treatment session.
8. Cognitive defusion skills. Clients participated in a series of exercises designed to identify and
defuse cognitive triggers, with particular emphasis on rationalizations for smoking. For example,
clients were taught to see thoughts as what they are (more or less helpful descriptors, depending
on the specific cognition), and not as what they say they are (infallibly accurate reflections of
reality). The goal of this component was to help clients alter the functions of cognitions that limit
achievement of their behavioral goals.
9. Behavioral activation and commitment. Clients practiced a range of adaptive responses in the
presence of negative affect and other internal triggers. The goal was to shape flexibility by
developing repertoires that provide realistic behavioral alternatives to smoking and other internal
triggers. The goal was to shape flexibility by developing repertoires that provide realistic
behavioral alternatives to smoking."
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Appendix 22
Hernandez-Lopez, Luciano, Bricker, Roales-Nieto, & Montesinos (2009) ACT Intervention (pp.
725-726).
"Several metaphors, paradoxes, examples, and experiential exercises, most of them drawn from
Hayes et al. (1999) and from Wilson & Luciano (2002), were used with the aim of clarifying the
value of quitting and of promoting the willingness and acceptance of thoughts, emotions, and
sensations related to quitting.
(a) Analyzing the personal cost of smoking as an attempt to control private events. The first
step was to make participants aware of the personal cost of smoking. For most of them smoking
was a control strategy that in the short run served to reduce anxiety, urges, or distress, although it
was ineffective long-term. The therapist illustrated how trying to control thoughts, emotions, and
sensations might not only be futile, but more importantly, have negative effects on certain valued
life domains (e.g., health, family).
(b) Values clarification and commitment with personal choices. The therapist helped
participants clarify their values and examine how quitting fits into a more meaningful life. They
were taught to identify and undertake specific actions oriented to quit (e.g., choosing how to quit,
either gradually reducing their cigarette consumption in one third each week, or “cold turkey,”
by setting a date for quit) and to detect psychological barriers (e.g., fear of withdrawal) to these
actions. They were encouraged to commit to taking valued actions.
(c) Defusion and willingness to experience and accept private aversive events. Participants
were trained to detect which internal and external triggers led them to smoking, and to
differentiate among those they could change (e.g., throwing away ashtrays) and those they could
not (e.g., being sad) or did not want to change because of the personal cost it would imply (e.g.,
by refusing to meet with friends who smoke you’ll probably have less urges, but you will lose
their companionship). The goal was to break the link between triggers and smoking behavior.
They were taught to see thoughts as thoughts, not as the cause of smoking. They also learned to
see themselves as the context in which urges and withdrawal symptoms occur, and were
encouraged to actively expose themselves to their private aversive events.
(d) Relapse as part of the process of quitting. No explicit difference was made between lapse
and relapse. Participants were trained to “notice when they were detouring from the direction
they wanted to follow,” and then to “get back to that direction” regardless of the intensity of
lapse (i.e., whether they had smoked a puff, a cigarette, or resumed smoking for some time).”

2

The intervention components by Hernandez-Lopez, Luciano, Bricker, Roales-Nieto, &
Montesinos (2009) (pp. 725-726) described above are reproduced verbatim from the source:
Hernandez-Lopez, M., Bricker, J. B., Roales-Nieto, J. G., & Montesinos, F. (2009). Acceptance
and commitment therapy for smoking cessation: A preliminary study of its effectiveness in
comparison with cognitive behavioral therapy. Psychology of Addictive Behaviors, 23(4), 723730.
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Appendix 33
Bricker et al.’s (2010) ACT-Telephone Session Outline.
SESSION 1: Core ACT processes of values and acceptance
SESSION 2: ACT processes of being present and committed action
SESSION 3: ACT processes of cognitive defusion and committed action
SESSION 4: ACT processes of self-as-context and committed action
SESSION 5: Material review and finalize a committed action plan for quitting

3

Schimmel-Bristow, A., Bricker, J. B., & Comstock, B. (2012). Can acceptance & commitment
therapy be delivered with fidelity as a brief telephone-intervention? Addictive Behaviors, 37(4),
517-520. doi: 10.1016/j.addbeh.2011.11.015
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